

Benzimidazoles and Imidazo[1,2-a]pyridines : Biological Activities, Method of Synthesis and Perspectives on Combination of Deuce Pharmacophore

Souleymane Coulibaly^{1*}, Ablo Evrard¹, Amit Kumar², Drissa Sissouma¹

¹Laboratoire de Constitution et Réaction de la Matière, UFR Sciences des Structures de la Matière et Technologie, Université Félix Houphouët Boigny de Cocody, 22 BP 582 Abidjan 22, Côte d'Ivoire.

²Université Paris Cité, CNRS, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, F-75006 Paris, France

*Corresponding author : souleydestras@yahoo.fr

Abstract

The N heterocyclic scaffold has generated a lot of interest among medicinal chemists. Of those potential heterocyclic drugs, benzimidazole and imidazopyridine scaffolds are considerably prevalent. They have gained tremendous importance over the past few decades. Both are an important class of molecules due to their wide spectrum of biological activities and clinical applications. Both are used in fashion design and the development of novel synthetic analogs for various therapeutic disorders. A wide variety of their derivatives have been developed as potential anti-cancer, anti-microbial, anti-viral, and anti-inflammatory besides other chemotherapeutic agents. Benzimidazole core was found in the natural system displaying a wide range of pharmaceutical properties and it gained significant attention in medicinal chemistry reported in several full articles and communications. While imidazopyridines exhibit a vast distribution in many pharmacologically important compounds shown by its frequent occurrence in a large number of marketed drug formulations and drug candidates as well as in other fields such as material and organometallic chemistry. These scaffolds are characterized as structurally potential ligands which can bind to different receptor sites for the discovery of various immerging drugs. They act as key pharmacophore motifs for the identification and optimization of lead structures to increase the medicinal chemistry toolbox. The present review outlines the synthesis and the medicinal significance of benzimidazoles and imidazopyridines for their development as lead molecules with improved therapeutic efficiencies. Here, we cover the various design used to obtain both heterocycles to establish a relationship between their combination to features the biological activities.

Keywords: Benzimidazole, Imidazopyridine, Heterocyclic scaffold, Biological activity, Pharmacophore synthesis

Introduction

Antimicrobial resistance (AMR) and worldwide increase in infections are recognized by the World Health Organization (WHO) as urgent risk for public health. The COVID-19 crisis, the monkeypox virus and their variants increase these risks into all domains, even worse on the world economy. AMR infections cause approximately 700 000 deaths annually, and they are expected to become the leading cause of death by the year 2050, especially in low- and middle-income countries.[1] To challenge this inauspicious outcome, the WHO launched strategic objectives and one of them set out incentivization of investments in the research of new pharmaceutical tools and medicines.[2] This latter strategic objective concerns chemists also. For this purpose, some intensification of research around nitrogen-fused azoles known as lead compound in the literature, pushed our curiosity and sum up it in this review. They have a wide range of applications in medicinal chemistry. Although benzimidazole and imidazopyridine are structurally different, their pharmacological properties are quite similar. Both heterocycles and their derivatives as well as preparative methods for basic derivatives are here presented.

This review article will focus on presenting the biological activities of benzimidazoles and their synthetic methods. Also imidazopyridine compounds are presented in the same way before their combination prospects are presented.

Indeed benzimidazole derivatives are heterobicyclic aromatic compounds resulting from the adhesion between benzene and imidazole. Due to their isostructural pharmacophore, molecules possessing in their basic structures the benzimidazole scaffold, have revealed a panoply of biological activities and among them we can mention the anticancer [3], acetylcholinesterase [4], antimicrobial [5], anti-inflammatory [6] analgesic [7], antiviral [8] anti-protozoan [9], antimalarial [10] and anti-leishmanial [11] activities. Benzimidazole scaffold are present in the structure of some commercial drugs such as Thiabendazole, Mebendazole, Luxabendazole, Triclabendazole, Albendazole and Oxibendazole (Figure 1).

Naturally, the wide applications and uses in a variety of fields have led to several synthetic routes developed for the production of imidazo[1,2-a]pyridines. In recent years, this has remained progress and innovation in the synthesis of imidazo[1,2-a]pyridines using several interesting

pathways, such as multi-component reactions, tandem sequences and C-H functionalization catalyzed by transition metals. These methods provide ease of obtaining imidazo[1,2-a]pyridines from simple and readily available precursors.

This has led to many discoveries concerning their biological properties including antimicrobial, anti-inflammatory, anticancer and antiparasitic properties, [12] thus dedicating this scaffold for molecular and biological explorations. The imidazo[1,2-a]pyridine core is also present in the structure of many drugs, which have good properties on the central nervous system. [13] Such is the case with Zolpidem, [14] a drug used to treat insomnia. Alpidem, Nécopidem and Saripidem, are three active ingredients used as an anxiolytic agent. [13] However, Alpidem was withdrawn from the market because of its toxicity. Olprinone, [15] is used in the treatment of acute heart failure. Zolimidine is active on *Escherichia Coli* (*E.Coli*) so used in the treatment of peptic ulcers. [16] An optically active drug with the imidazopyridine motif in its skeleton, GSK812397 is intended for the treatment of HIV infection. [16]




Figure 1: some drugs based on the benzimidazole scaffold

I. Benzimidazoles and Derivatives : Biological Activities and Synthesis Methods

1. Biological Activities of benzimidazole derivatives

a. Antimicrobial properties

Several benzimidazole derivatives are described in the literature and, have shown excellent antimicrobial activity.[17-18] The work of Ramya V. Shingalapur et al. [19] provided access to benzimidazole molecules with interesting antimicrobial activities. In this work, the derivatives of 2-styryl-1*H*-benzimidazole (Figure 2; **1-3**) showed good antimicrobial activity *in vitro* on two Gram-positive strains (*Staphylococcus aureus* ATCC25923 and *Enterococcus faecalis* ATCC29212) and four Gram-negative strains (*Klebsiella pneumoniae* ATCC13883, *Escherichia coli* ATCC-25922, *Albicans candida* ATCC10145 and *Asperigillus fumigatus*). All of the evaluated compounds showed good antibacterial properties with Minimum Inhibitory Concentrations (MICs) between 16 and 1 µg/mL. Of these compounds, 3-[2-(5-bromo-1*H*-benzimidazol-2-yl)-vinyl]-phenol showed the best activity on all strains with MIC values between 1 µg/mL and 4 µg/mL (**1-3**, Figure 2).

Muayed Redayan et al.[20] have shown that 5-(((1*H*-benzimidazol-2-yl)methyl)thio)-1,3,4-thiadiazol-2-amine derivatives (**4-6**, Figure 2) present interesting antibacterial activities comparable to existing standard antibiotics such as Ampicillin and Ciprofloxacin. During this work, the synthesized compounds were screened for their antibacterial activities against Gram-negative (*E. coli*, *P. aeruginosa*) and Gram-positive (*B. subtilis*, *S. aureus*) bacteria. Most of these derivatives showed good antibacterial activity against all strains.

Amino-(2-(4-(((1-benzyl-1*H*-1,2,3-triazol-4-yl)methyl)amino)phenyl)-1*H*-benzimidazol-5yl) methaiminium (**7**, Figure 2) was evaluated for antibacterial activity *in vitro* on two Gram-positive strains (*S. Aureus* ATCC 25923 and *Enterococcus Fasalis* (ATCC 29212) and five Gram-negative strains (*E. coli* ATCC 25925, *K. pneumoniae* ATCC 700803, *P. Aeruginosa* ATCC 27853 and *Acinetobacter Baumannii* ATCC 19606). The results of the antibacterial activity of this benzimidazole-derived compound showed very good properties on Gram-positive strains compared to antibiotics such as Ceftazidime, ciprofloxacin, ampicillin and gentamicin.[21]




Figure 2: Compound with good antimicrobial activities-A. 2-styryl-1H-benzimidazole derivatives, B. 5-(((1H-benzimidazol-2-yl)methyl)thio)-1,3,4-thiadiazol-2-amine derivatives, C. Amino-(2-(4-(((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)amino)phenyl)-1H-benzimidazol-5-yl) methaniminium.

b. Antifungal properties of benzimidazole derivatives

The antifungal activity of the benzimidazole scaffold was first reported in 1944 by Woolley[22], [23] through chlormidazole or 1-(4-chlorobenzyl)-2-methyl-1H-benzimidazole. It became a fairly well-known activity of benzimidazole that has generated behind a lot of research.

Mishra et al. [24] showed that the 2-chloromethyl-5H-methylbenzimidazole derivatives substituted in the -2 position by 5-mercapto-1,3,4-oxadiazole or 4-amino-5-mercapto-1,2,4-triazole showed good antifungal activity on *Rhizoctonia solani* and *Helminthosporium oryzae* fungi.

In the same vein, antifungal activities of the benzimidazole core were also highlighted by Gulgun Ayhan et al.[25]. For example, *in vitro* testing of *Candida albicans* (*C.albicans*), *Candida glabrata* (*C.glabrata*) and *Candida krusei* (*C. krusei*) strains showed that 5-amino-2-(p-fluorophenyl)-1-propylbenzimidazole (9) and 2-(p-fluorophenyl)-5-nitro-1-propylbenzimidazole (Figure 3) are potent on these strains with a large antifungal activity spectrum. These benzimidazole compounds were more active on *C. albicans* with a MIC of 12.5 g/mL compared to the reference antibiotic Fluconazole. For the *C. Krusei* strain, compounds such as 5-amino-2-(p-fluorophenyl)-1-propylbenzimidazole, 2-(p-fluorophenyl)-5-nitro-1-propylbenzimidazole (8) and N-[2-(p-fluorophenyl)-1-propyl-benzimidazol-5yl]-N-(p-chlorophenyl)-thiourea were more effective with MICs of 5 to 6.25 g/mL.

Finally, Göker et al.[26] also evaluated the *in vitro* antifungal activity of 5-carbonitrile benzimidazole. This compound was very active on strains such as *C. albicans*, *C. grabrata*, *C. krusei* and *C. parapsilosis* with an activity similar to that of Fluconazole.




Figure 3: 2-(4-fluorophenyl)-1-propyl-1*H*-benzimidazole derivatives with antifungal activities.

c. Anticancer properties of benzimidazole derivatives

The anticancer activity of benzimidazole derivatives has been described in several research studies [27], [28]. Among these works, we will mention those carried out by Hanan Refaat[29] on the determination of the anticancer activity of 2-substitued benzimidazole derivatives. The cytotoxicity of these benzimidazole compounds was evaluated on three cell lines representing three common forms of human cancer, namely a human hepatocellular carcinoma cell line (HePG2), a human breast adenocarcinoma cell line (MCF7) and a colon carcinoma cell line (HCT 116). In this work, they were able to show that the position-2 substituted benzimidazole derivatives have anticancer activity against all tumor cell lines with an IC_{50} of less than 10 mg/mL. Generally, all compounds tested tended to be more active against HePG2 and other tumor cell lines. 5-chloro-2-[(4-fluorobenzylidene)cyanomethyl]benzimidazole and 2-(4-amino-3-benzyl-2-thioxo-2,3-dihydrothiazol-5-yl)benzimidazole-5-carboxylic acid showed the most increased activity against HePG2 while 2-[(cyclohexylidene)cyanomethyl]benzimidazole-5-carboxylic (**10**), 5-chloro-2-[(3-phenyl-4-oxothiazolidin-2-ylidene)ciano-methyl]benzimidazole (**11**) and 2-[3-(4-bromophenyl)-4-(2-methoxyphenylthiazol-2-ylidene)cyanomethyl]benzimidazole-5-carboxylic acid (**12**) were most active against MCF7 (Figure 4).

Salahuddin et al.[30] also synthesized derivatives of 2-(naphthalen-1-ylmethyl/naphthalen-2-yloxymethyl)-1-[5-(substituephenyl)-[1,3,4]oxadiazol-2-ylmethyl]-1*H*-benzimidazole. In this work, they showed that 2-naphthalen-1-ylmethyl-1-[5-(4-nitro-phenyl)-[1,3,4]oxadiazol-2-ylmethyl]-1*H*-benzimidazole (**13**, Figure 4;) had good anticancer activity on certain lines such as leukemia, melanoma, lung cancers, colon, central nervous system, ovary, kidney, prostate and breast at a single high dose around 10^{-5} M.

The 2-(benzimidazol-2-yl)methylthio-4-(substitued)-6-phenylpyrimidine-5-carbonitrile derivatives synthesized by Abdel-Mohsen et al.[31] were evaluated for their anticancer activities

against twelve cancer cell lines KB, SKOV-3, SF-268, NCI-H460, RKOP27, HL60, U937, K562, G361, SK-MEL-28, GOTO and NB-1. All of these benzimidazole derivatives evaluated *in vitro* showed good anticancer activity on the various cancer lines.




Figure 4 : Anticancer properties possessed by A. Benzimidazole derivatives against HEPG2 and MCF-7, B. 2-naphthalen-1-ylmethyl-1-[5-(4-nitro-phenyl)-[1,3,4]oxadiazol-2-ylmethyl]-1H-benzimidazole.

d. Anthelmintic properties of benzimidazole derivatives

The anthelmintic activity is one of the main properties recognized for benzimidazole derivatives. [32]–[34] Some of these compounds are used to fight parasitic diseases such as helminthiases. This is the case for Flubendazole, Mebendazole, Albendazole and Thiabendazole. Also, new derivatives of 2-((1*H*-benzimidazol-2-yl)thio)-1-(piperazin-1-yl)ethan-1-one were synthesized (Figure 5- compound **16**) by Mavrova et al.[35] showed strong anthelmintic activity *in vitro* against *Trichinella spiralis*. This activity was higher than that observed on the same germ when using a drug such as Albendazole.

Ramesh Sawant et al.[36] also showed that the new 2-phenyl benzimidazole-1-acetamide derivatives possess anthelmintic activities. Thus, anthelmintic tests have been carried out using the derivatives of 2-(((1*H*-benzimidazol-2-yl)methyl)thio)-5-phenyl-1,3,4-thiadiazole (Figure 5- compound **18**) on *Pheretima Posthuma* which is an authenticated worm at the University of SSGM (Shri Sadguru Gangageer Maharaj Sciences) in India.

This work revealed that these derivatives at the -2 position have an excellent anthelmintic activity.




Figure 5: Benzimidazole derivatives with anthelmintic derivatives

e. Antiviral properties of benzimidazole derivatives

Several research studies have shown that benzimidazole derivatives substituted in position-1 or -2 have good antiviral properties too.[37-38] Erik De Clercq and Laura Garuti[39] synthesized benzimidazole derivatives substituted in position-1 by sulfonyl. Subsequently, the antiviral activity of these derivatives was evaluated against *Human cytomegalovirus* and *Varicella-zoster virus*. Among evaluated compounds, the 5,6-dichloro-1-(isopropylsulfonyl)-2-(2-(pyridin-2-yl)ethyl)-2,3-dihydro-1*H*-benzimidazole (Figure 6.compound **20**) showed the best antiviral activity against the different strains with an IC_{50} of 1.6 to 1.1 mg/mL. In the same study, some benzimidazole-coumarin derivatives have shown excellent activities against the *hepatitis C virus* with IC_{50} between 3.4 μ M and 4.1 μ M.

Antiviral activity was also shown through the work of Deepika Sharma et al.[40] on the 4-nitrophenyl-2-phenyl-1*H*-benzimidazol-1-ylmethanone derivatives. The demonstration of the antiviral properties of these derivatives was done. In addition, these authors showed that 4-nitrophenyl-2-(4-chlorophenyl)-1*H*-benzimidazol-1-ylmethanone and 2-bromophenyl-2-phenyl-1*H*-benzimidazol-1-ylmethanone (Figure 6-compounds **21** and **22**) were likely good candidates for the manufacture of an antiviral vaccine.




Figure 6 : Benzimidazoles derivatives with antiviral activities

f. Anti-inflammatory properties of benzimidazole derivatives

The anti-inflammatory activity of benzimidazole derivatives has been reported through several research studies.[41-42] However, the benzimidazole molecules (Figure 7. Compounds **23-25**) discussed in this section are those that have shown good anti-inflammatory properties in the work of Monika Gaba *et al.*[43]. Indeed, in this work, the anti-inflammatory activity of the molecules was compared with those of reference drugs such as Indomethacin, Nimesulide, Ibuprofen and Diclofenac. These benzimidazole derivatives showed activities above certain reference drugs. Kavitha Achar *et al.*[44] also highlighted the anti-inflammatory activity of benzimidazole derivatives. These authors showed that some derivatives of N-((1*H*-benzimidazol-2-yl)methyl)aniline (Figure 7. Compounds **26-27**) had very good anti-inflammatory activities. This study was conducted using Nimesulide as a reference drug.




Figure 7 : A. Benzimidazole derivatives (**23-25**).^{ref.43} B. N-((1*H*-benzimidazol-2-yl)methyl)aniline derivatives with good anti-inflammatory activities (**26-27**).^{ref.44}

g. Anti-leukemia properties of benzimidazole derivatives

This biological property of benzimidazole derivatives was revealed through the work of Thimme Gowda *et al.*[45] on the synthesis and evaluation of the anti-leukemia activity of new 1-(4-methoxyphenethyl)-1*H*-benzimidazole-5-carboxylic acid derivatives. The screening of twenty-two (22) new synthesized compounds showed that methyl 2-(4-fluoro-3-nitrophenyl)-1-(4-methoxyphenyl)-1*H*-benzimidazole-5-carboxylate (Figure 8) was a good anti-leukemic properties. This molecule inhibits human leukemia cells with an IC₅₀ of 3 μ M.




Figure 8: Structure of methyl 2-(4-fluoro-3-nitrophenyl)-1-(4-methoxyphenethyl)-1H-benzimidazole-5-carboxylate

h. Anti-plasmodial properties of benzimidazole derivatives

In our group, Ouattara Mahama et al.[46] demonstrated the antiplasmodial behavior of benzimidazole through the synthesis and evaluation of benzimidazolyl-chalcone derivatives (Figure 9-compounds **29**, **30**). In their work, anti-plasmodial screening of *Plasmodium Falciparum* (*P. falciparum*) chloroquino-sensitive and chloroquino-resistant isolates has shown that benzimidazolyl-chalcones are excellent antiplasmodial pharmacophores. Indeed, 1-(fluoro-1H-benzimidazol-2-yl)-3-phenylprop-2-en-1-one (compound **29**) with an IC₅₀ value of 5.63 μM showed the best profile on the chloroquino-sensitive *P. falciparum* isolate.

Bandyopadhyay et al.[47] synthesized and evaluated the antimalarial activity of benzimidazole phosphorylated derivatives against *Albopictus* and *Culex Quinquefasciatus* mosquitoes. They showed that dimethyl-(4-(1H-benzimidazol-2-yl)phenyl)phosphoramidate (Figure 9-compound **31**) was more potent on *Albopictus* and *C. Quinquefasciatus*.

Camacho et al.[48] synthesized benzimidazole derivatives to test *in vitro* antimalarial activities to inhibit the formation of β-hemetic (IβHS) responsible for hemoglobin hydrolysis. But also, *in vivo* study was done on a rodent like the *Plasmodium Berghei*. Among these tested molecules, 2-(5-nitrofuran-2-yl)-3H-benzimidazole-5-carboxylic acid (Figure 9-compound **32**) showed the most inhibition of β-hemetic formation, meaning the best antimalarial activity.

Divatia et al.[49] synthesized thiosemicarbazones supported by the benzimidazole scaffold and evaluated their antimalarial activity *in vitro* against *P. falciparum* in comparison to chloroquine and quinine as reference molecules. Some of the compounds synthesized include (E)-2-[1-(5-chloro-1H-benzimidazol-2-yl)ethylidene]-N-(benzoyl)hydrazine carbothioamine, (E)-2-[1-(5-chloro-1H-benzimidazol-2-yl)ethylidene]-N-(4-fluorophenyl)hydrazine carbothioamine and (E)-2-2-[1-(5-chloro-1H-benzimidazol-2-yl)ethylidene]-N-(4-iodophenyl)hydrazine carbothioamine have shown excellent antimalarial activities. Indeed, the structure-activity relationship study

conducted suggests that compounds with mesomeric electron donor groups (EDG) such as halogen had excellent antimalarial activity (Figure 9-compound **33**).

The work conducted by Toro et al.[50] on the synthesis and evaluation of the anti-plasmodial activity of benzimidazole derivatives. The anti-plasmodial tests were carried out *in vitro* against *P. falciparum* on compounds such as 2-ferrocenyl-benzimidazole and N-ferrocenylmethyl-2-ferrocenyl-benzimidazole (Figure 9-compound **34**). These molecules showed good anti-plasmodial properties with IC₅₀ between 10.4 to 26.5 μM.




Figure 9 : Benzimidazole derivatives with antiplasmodial activity

i. Antioxidant properties of benzimidazole derivatives

Sarika Saini et al.[51] showed that the 2-methyl-1*H*-benzimidazole has an interesting antioxidant activity. Using 2,2-diphenyl 1-picrylhydrazyl (DDPH), they were able to show that 2-methyl-1*H*-benzimidazole (Figure 10. Compound **35**) had a higher antioxidant activity than ascorbic acid at higher concentrations.

The antioxidant activity of benzimidazole was demonstrated in the work of Dvornikova et al. [52]. They evaluated this activity with 2-hydroxyphenyl benzimidazole derivatives (Figure 10. Compounds **36-37**) using the *in vitro* method and compared it to a few reference molecules. It was shown that the compounds possessing the phenol group with substituents such as isobornyl and tert-butyl showed a much higher antioxidant activity than the references.

R. A. Sabrina et al. [53] evaluated the antioxidant activity of some 5-nitrobenzimidazole derivatives (Figure 10. Compounds **38-40**) in their work. Indeed, they proved that all the 5-nitro-2-substituted benzimidazole derivatives that they synthesized had an antioxidant activity far

superior to the reference molecule with minimum inhibitory concentrations between 3.17 to 7.59 $\mu\text{g/mL}$.




Figure 10: A. 2-methyl-1*H*-benzimidazole B. 2-hydroxylphenyl benzimidazole derivatives C. 5-nitrobenzimidazole derivatives

2. Methods for Benzimidazole and derivatives synthesis.

Benzimidazole is one of the oldest nitrogen heterocycles. It was first synthesized by Codebreaker in 1872 and then later repeated in 1878 by Ladenburg and Wundt [54]. Since then, several synthetic methods have been developed to obtain functionalized benzimidazole mainly at positions -1, -2, -3 and -5.

a. The Phillips methods

In 1928, Phillips synthesized 2-substituted benzimidazole derivatives by reacting orthophenylenediamine (OPDA) with various organic acids in 4N hydrochloric acid under reflux for 30 to 40 minutes [55]. These 2-substituted benzimidazole derivatives (**43**) were obtained with yields ranging from 50 to 70 % (Figure 11.A). This method is the most used to obtain benzimidazole derivatives. Carboxylic acid derivatives can be replaced by mercaptoacetic acid. El-Gohary et al.[56] were able to synthesize 2-mercaptomethyl-1*H*-benzimidazole (**45**) by condensation of mercaptoacetic acid with OPDA under the same conditions as in the Phillips reaction (Figure 11.B). By condensing OPDA with benzoic acid derivatives, Odame et al.[57]

synthesized substituted benzimidazole derivatives at the 2-position (**47**). This reaction occurred in toluene at reflux for 6 hours in the presence of polyphosphoric acid (PPA) (Figure 11.C). Saini et al.[51] did the same kind of work, condensing OPDA with 90 % acetic acid at a temperature of 100°C for 2 hours. After treatment of the reaction medium, they obtained 2-methyl-1*H*-benzimidazole (**49**) with a yield of 72 % (Figure 11.D).




Figure 11: A. Benzimidazole synthesis by Phillips method. B. Synthesis of 2-mercaptomethylbenzimidazole. C. Synthesis of 2-m-tolyl-1*H*-benzimidazole according to Odame et al. D. Synthesis of 2-methyl-1*H*-benzimidazole according to Saini et al.

b. Synthesis method from orthophenylenediamine and aldehydes

The synthesis of benzimidazole from the condensation between OPDA and aldehydes are commonly the most described in the literature. The reactions of obtaining benzimidazole derivatives from OPDA and aldehydes using hydrogen peroxide (H₂O₂) and hydrochloric acid (HCl) solution at 100°C (Figure 12.A) have been described by Kiumars Bahrami et al.[58]. This method made possible to obtain benzimidazole derivatives substituted in position -2 by aryl groups with yields ranging from 85 to 96 %. Shortly thereafter, same authors repeated the process at room temperature this time, replacing the water by acetonitrile[59]. This method has been used in other

works. Hydrochloric acid (HCl) was replaced by cerium ammonium nitrate (CAN) and resulted in the production of 2-aryl-1*H*-benzimidazole with yields between 92 and 97 % (Figure 12.B) [60]. In another study, Li-Hua Du et al.[61] also synthesized 2-substituted benzimidazole derivatives. They condensed OPDA derivatives with benzaldehyde derivatives in various organic solvents in the presence of iodobenzenediacetate (IBD) as an oxidizing agent. This reaction took place at room temperature for 3 to 5 min to obtain substituted benzimidazole at the -2 position with yields ranging from 68 to 98 %. The best yields were obtained by using dioxane as a reaction solvent (Figure 12.C).Karthikeyan et al.[62] synthesized derivatives of 2-aryl-1*H*-benzimidazole substituted in position-5 by the carboxylic acid function (Figure 12.D). They put in reaction 3,4-diamino benzoic acid or 3,4-diamino ethyl benzoate with benzaldehyde derivatives in *N,N*-dimethyl acetamide (DMAc) at 100°C for 6 to 12 h in the presence of sodium metabisulfite (Na₂S₂O₅).

The condensation of OPDA with furan carbaldehyde derivatives in ethanol at room temperature resulted in a series of benzimidazole substituted in the -2 position by furan[63] with a yield of 90 % for two hours. This reaction was catalyzed by copper II associated with a Schiff base (Figure 12.E).The synthesis of 2-alkyl-1*H*-benzimidazoles from OPDA and aldehydes was also performed by Alloum et al.[64]. This synthesis method involved the reaction of various aldehyde derivatives with OPDA on a solid base (silica SiO₂ treated with thionyl chloride SOCl₂) in DCM at room temperature (Figure 12.F). This reaction occurs through the formation of imine intermediate, followed by aromatization by sulfur dioxide formed *in situ* to lead to the substituted benzimidazole derivatives in position-2.




Figure 12: A. Synthesis of 2-aryl-1*H*-benzimidazole according to Kiumars Bahrami *et al.* B. synthesis of 2-aryl-1*H*-benzimidazole. C. Synthesis of the derivatives of 2-phenyl-1*H*-benzimidazole according to Li-Hua Du *et al.* D. Synthesis of derivatives of 2-aryl-1*H*-benzimidazole according to Karthikeyan *et al.* E. Synthesis of 2-substituted benzimidazole catalyzed by a Schiff base. F. 2-substituted benzimidazole synthesis according to Alloum *et al.*

c. Synthesis method of benzimidazole derivatives from aniline derivatives

The synthesis of benzimidazole from aniline and aldehyde derivatives is most often catalyzed by transition metals. Some of these reactions are carried out in the presence of catalysts which possess oxidation or reduction properties. The work of Devuapally Mehshesh *et al.*[65] present the synthesis of benzimidazole derivatives by reacting aniline with primary amines (benzylamine) in the presence of sodium azide (NaN₃) and copper II used as catalyst in dimethylsulfoxide (DMSO) at a moderate temperature. To improve the efficiency of this method, *ter*-butyl hydroperoxide

(THBP) and acetic acid derivatives were added to the reaction medium. This reaction worked in 10 h in the range of 52 to 79 % yield (Figure 13.A). In the same work, benzylamine derivatives were replaced by benzylic alcohol derivatives. They obtain benzimidazoles with yields ranging from 35 to 62 %, but with a longer reaction time than that of benzylamines (Figure 13.B).

Yong Kim *et al.* [66] obtained benzimidazole derivatives by reacting the 2-halogeno anilines with the aromatic aldehydes for 12 h under reflux of dimethyl sulfoxide (DMSO). They were synthesized with yields ranging from 44 % to 98 %. The best yields were obtained with 2-iodoaniline in the presence of ligands such as 1,2-Dimethylethylenediamine (DMEDA) and Tetramethylethylenediamine (TMEDA) (Figure 13.C). Thanh N'guyen *et al.* [67] synthesized a 2-substituted benzimidazole variety without using an organic solvent. They condensed 2-nitroaniline with benzylamines in the presence of iron chloride for 24 h at 120°C. The 2-substituted benzimidazole derivatives were obtained with yields between 58 and 92 % (Figure 13.D). The production of benzimidazole derivatives was first described in 1872 by Hobbrecker [68]. This method is one of the oldest methods to access to the benzimidazole scaffold. After a reduction of 2-nitro-5-methylacetanilide, an intramolecular cyclization followed and yielded to 2,5-dimethyl-1*H*-benzimidazole (Figure 13.E).




Figure 13: synthesis of the derivatives of 2-phenyl-1*H*-benzimidazole using benzylamine according to Devuapally Mehshesh *et al.* B. synthesis of the derivatives of 2-phenyl-1*H*-benzimidazole using phenylmethanol according to Devuapally Mehshesh *et al.* C. synthesis of the derivatives of 2-phenyl benzimidazole according to Yong Kim *et al.* D. synthesis of benzimidazole-2-substituted derivatives according to Thanh N'guyen . E. Hobrecker synthesis of 2-methyl-1*H*-benzimidazole

d. Method of synthesis from orthophenylenediamine (OPDA) derivatives and N-substituted formamide and amidinium salts

Deepak Nale *et al.* [69] synthesized derivatives of N-alkylbenzimidazole (73) by reacting a variety of OPDA with formamide N-substituted with zinc diacetate ($\text{Zn}(\text{OAc})_2$) as a catalyst in the presence of poly(methylhydrosiloxane) (PMHS) for 18 h at 120°C (Figure 14.A). In our group, we

worked also on the synthesis of benzimidazole scaffold. We developed a method by Sissouma Drissa *et al.* [70], [71] in which, a thioalkyl or thioaryl group of amidinium salts was introduced to the -3 position. The condensation of these amidinium salts with OPDA in dichloromethane provided access to the 2-thioalkylbenzimidazole (**76**) and 1*H*-benzimidazole derivatives (Figure 14.B).




Figure 14: A. Synthesis of N-substituted benzimidazole derivatives according to Deepak Nale. B. Synthesis of benzimidazole and 2-thiobenzimidazole according to Sissouma *et al*

e. Synthesis method from benzodiazepines

We also developed another method in a work done by Timotou *et al.* [71]. We were able to synthesize benzimidazole derivatives by cyclic regression of benzodiazepines (**79**). This method consisted of treating chalcones (**77**) in an alkaline medium to access benzodiazepine derivatives (**79**). Then, these benzodiazepines were treated under DMF reflux in the presence of potassium carbonate (K_2CO_3) for 24 h to obtain the benzimidazole derivatives. Camara *et al.* [72] repeated this method by treating benzodiazepine formed either in acid or basic medium under DMF reflux for 2 h. The yields have been improved in acid medium, between 60 and 80%, while in basic medium, the yields varied between 40 and 60% (Figure 15).




Figure 15: synthesis of derivatives of 2-aryl benzimidazole according to Camara *et al.*

f. Method of synthesis from OPDA derivatives and other reagents

By reacting OPDA with ethyl acetoacetate under reflux of xylene for 6 h, Denise Mondieig *et al.* [73] were able to synthesize benzimidazole by introducing the isopropenyl group into position-1. Thus, they obtained N-isopropenylbenzimidazolone with a yield of 70 % (Figure 16.A).




Figure 16: A. Synthesis of N-alkylbenzimidazolone derivatives according to Denise Mondieig *et al.* B. synthesis of N-alkylbenzimidazolone derivatives according to Vakhid Mamedovet *et al.* C. synthesis of derivatives of 2-aminobenzimidazole Leonard *et al.* D. Albendazole synthesis method. E. Synthesis of 1,3-bis(1*H*-benzimidazol-2-yl)benzene according to Yang *et al.*

The same method was used by Vakhid Mamedov *et al.* [74] to describe the synthesis of benzimidazolone derivatives through the formation of a reactive intermediate, benzodiazopinone. Once isolated, it was treated under reflux of methoxyethanol, allowing a rearrangement to lead to benzimidazolone derivatives with a yield of 60% (Figure 16.B). The 2-amino-5-chlorobenzimidazole was synthesized by Leonard *et al.* [75] by a reaction between p-chloro-OPDA and cyanogen bromide (BrCN). This reaction was carried out in the presence of hydrochloric acid in an EtOH/H₂O mixture at 70 °C. Thus, after cooling, the reaction medium was neutralized with a sodium hydroxide solution to give 2-amino-5 chlorobenzimidazole with a yield of 73 % (Figure 16.C). By applying the Phillips method to iminoester [76] and thiocarbamate [77] acid derivatives, benzimidazole derivatives were synthesized by reacting thiocarbamates with OPDA derivatives in an aqueous solution of sodium hydroxyde. This reaction resulted in Albendazole analogues after the removal of the thiol group and ammonia (Figure 16.D). Yang *et al.*[78] synthesized bisbenzimidazole through a condensation reaction of an excess of OPDA with 1,3-bis(dibromomethyl)benzene to produce 1,3-bis(1*H*-benzimidazol-2-yl)benzene with a yield of 87% (Figure 16.E).

g.Method of synthesis from derivatives of orthophenylenediamine and carbon disulfide

The synthesis of the derivatives of 2-mercapto-1*H*-benzimidazole was carried out according to the method described by Van Allan *et al.*[79].

Thus, the action of carbon disulfide on OPDA derivatives in dimethylformamide (DMF) under magnetic agitation for 24 h leads, after addition of water into the reaction mixture to the formation of 2-mercapto-1*H*-benzimidazoles (Figure 17.A). By replacing carbon disulfide with urea, Bhanage *et al.* [78] synthesized 1,3-dihydrobenzimidazol-2-one. For this purpose, they condensed OPDA with urea in DMF at 150°C. They obtain 1,3-dihydrobenzimidazol-2-one with a 98% yield (Figure 17.B).




Figure 17: A. Synthesis of mercapto-1H-benzimidazole according to Van Allan *et al.* B. Synthesis of 1,3-dihydrobenzimidazol-2-one according to Bhanage *et al.*

II. Imidazo[1,2-a]pyridines : Biological Activities and Synthesis Methods

Imidazo[1,2-a]pyridines are aromatic bis-heterocyclic compounds resulting from the addition of an a-type fusion of pyridine and imidazole rings with angular nitrogen connecting the two cycles. Depending on the position of the pyrrolic nitrogen and also the angular one, three isomers are obtained (**Figure 18.A**) Imidazopyridine is an important pharmacophore because it is widely used in many biologically active compounds. A multitude of research works has been done around this bis-heterocyclic, and even some drugs came from those researchs.




Figure 18 : A.Three imidazopyridine isomers B. Few drugs based on Imidazopyridine scaffold

II-1. Biological activities of the imidazopyridine scaffold

According to the pharmacomodulations undertaken on the different positions of the imidazo[1,2-a]pyridine moiety, in particular on the pyrrolic core, interesting biological activities are obtained. These have been described in the literature. Furthermore, the most common biological activities will be mentioned.

a. Imidazo[1,2-a]pyridine as antimicrobial agent

The antibacterial activity of imidazo[1,2-a]pyridine derivatives has been proven by Pushpalatha Budumuru *et al.*[80] on various strains, including *in vitro* antimicrobial activities against *E. coli* (ATCC-25922), *S. aureus* (ATCC-9144), *K. pneumoniae* (ATCC-13883) and *B. subtilis* (ATCC-6051). The study was performed against the reference drug Streptomycin and the inhibition zones

were calculated. Thus all their synthesized compounds, at a concentration of 1000 µg/mL, showed a promising inhibition against the various microbial pathogens tested. Of the compounds synthesized (Figure 19), compounds **100a**, **100c**, **100e** and **100g** containing benzyl, 4-fluorobenzyl, 4-methylbenzyl and 4-methoxybenzyl substituents demonstrated inhibition against all pathogens. The 9c and 9e compounds with 4-fluorobenzyl and 4-methylbenzyl as their respective substituents showed moderate activity against *E. coli*. In addition, compounds **100e**, **100g** and **100j** containing 4-methylbenzyl, 4-methoxybenzyl and 3,4,5-trifluoromethylbenzyl substitutes showed inhibition against *K. pneumoniae*. All synthesized compounds showed less activity against *S. aureus*. Similarly, no activity was recorded by the compounds **100a**, **100b**, **100d**, **100g**, **100h**, **100i** and **100l** at their lowest concentrations (500 µg/mL) tested against *K. pneumoniae*.

In addition, the work of Kai et al.[81] has led to the antimycobacterium (*Tuberculosis* bacteria) activity of new imidazo[1,2-a]pyridine-3-carboxamide derivatives. Thus, they proved that compounds with donor groups on the phenyl nucleus, had excellent antimycobacterial activity against two MTB H37RV drugs and drug-resistant clinical isolates with inhibition concentrations between 0.0041 to 2.64 µM.




Figure 19 : Imidazo[1,2-a]pyridine derivatives by Pushpalatha Budumuru et al. against *E. coli* (ATCC-25922), *S. aureus* (ATCC-9144), *K. pneumoniae* (ATCC-13883) and *B. subtilis* (ATCC-6051)

b. Imidazo[1,2-a]pyridine as an anticancer agent

Various *in vitro* studies have shown that several imidazopyridine-based compounds have potential therapeutic effects against different cancer cell lines. These include breast, liver, colon, brain, lung and kidney cancers. [82] The anticancer effects of these compounds are primarily the result of their inhibitory effects on different molecular mechanisms. Namely, PI3K/ AKT, CENP-E, IGF-1R, CDK, inhibition of tubulin polymerization and C-encounter inhibition.

Similarly, Gui-Ting Song et al. [83] initiated modulations around the imidazopyridine core conferring anticancer activities. Thus the modulations at the -2 position by phenyl derivatives and at the -3 position by quinoxaline (**101**) and quinoxalone (**102**) derivatives led to imidazo[1,2-a]pyridine derivatives that inhibited tumour cell proliferation. This is the case with compounds (**101**) and (**102**) at the 20 μM concentration, which over 48 hours showed a very high inhibition rate on HCT-116, HeLa and MCF-7 cells.

The anticancer activity of the imidazopyridine nucleus was also demonstrated by Nurit Dahan-Farkas et al.[84] on colon cancer. For this purpose, the 6-substituted imidazo[1,2-a]pyridines compounds they synthesized were evaluated for their anticancer activities on the HT-29 and Caco-2 cell lines. Thus, all compounds bearing a 6-position nitro-substituent (NO_2) in the imidazopyridine nucleus and all those bearing a 2,5-dihydroxyphenyl substituent attached to imidazopyridine, showed little reduction in cell growth of colon cancer cell line. In contrast, imidazopyridine derivatives containing the protected hydroxyl group (such as OMe, compound **103**) and the nitrogen-substituted phenyl group (compound **104**) generally performed well by reducing the cell viability tested by more than 50% with concentration values inhibitions well above 50 μM .




Figure 20 : Modulations around the imidazopyridine core conferring anticancer activities.

c. Imidazo[1,2-a]pyridine as an antiplasmodial

The antiplasmodial activity of the imidazo[1,2-a]pyridine motif was demonstrated in our group and published by Mahama Ouattara et al.[85] We designed by juxtaposition of anti-infectious moieties, a series of hybrid imidazopyridinyl-arylpropenone compounds and performed the anti-plasmodial screening of five imidazopyridinyl-arylpropenone derivatives using the Rieckmann method, followed by the determination of HRP2 antigen production by ELISA on chloroquino-sensitive and chloroquino-resistant *P. falciparum* isolates. The analysis of antiplasmodial activities was translated into an inhibitory concentration of 50 (IC_{50}) and expressed in micromoles (μM). Their

results on the chloroquino-sensitive *Plasmodium falciparum* isolates reveal that the **106** and **6y** compounds (IC_{50} = 35.92 and 24.08 mM respectively) have moderate antiplasmodial activity, while the other three (**105**, **107** and **108**) possess have very good antiplasmodial activities, between 8.65 and 6.23 mM. Five imidazopyridinyl-arylpropenone compounds (**105**, **106**, **107**, **108** and **109**) were found to be very active on *P. falciparum* chloroquino-resistant isolates.




Figure 21: 3-(phenyl)-1-(2-methyl*H*-imidazo[1,2-*a*]pyridin-3-yl)prop-2-en-1-one derivatives against *Plasmodium Falciparum*

d. Imidazo[1,2-*a*]pyridine as an antiviral agent

The antiviral activity of the imidazopyridine scaffold has been demonstrated by researchers since the 1990s. Thus, Chafiq Hamdouchi *et al.* [86] was able to show that some derivatives of 2-amino-3-substituted-6-[-1-phenyl-2- (N-methylcarbamoyl) vinyl] imidazo [1,2-*a*]pyridines (compounds **110**, Figure 22) had strong anti-rhinovirus activity and no obvious cell toxicity.

Alain Gueiffier [87] *et al.* performed chemical modifications at the position-3 of the imidazo [1,2-*a*]pyridine ring. This improved the therapeutic index of this new class of antiviral agents. Thus, antiviral as says on the series of their molecule have shown that some of their compounds (compounds **111** and **112**) appear to be as the most potent and selective inhibitors of CMV and VZV compared with three reference drugs such as ganciclovir, acyclovir and brivudin.

Several sugar-substituted imidazopyridine derivatives showed significant activity against human cytomegalovirus. Indeed, the evaluation of their activities against two selected herpes and cytotoxicity studies demonstrated that racemic 2,6-dichloro-3- (β -D / L-Erythrofuranosyl)imidazo[1,2-*a*] Pyridine and 2,6-dichloro-3-(α -D / L-Erythrofuranosyl)

imidazo[1,2-a]pyridine (compound **114**) were both inactive against HCMV and HSV-1 and nontoxic on uninfected cells.[88] [89] In contrast, the enantiomer mixture of 2,6,7-trichloro-3- (α -D/L-Erythrofuransyl)imidazo[1,2-a]pyridine (**113**) was active against HCMV and HSV-1. They noted that the α (10) anomer is more active than the β anomer.




Figure 22 : Imidazopyridine derivatives with antiviral activities

e. Imidazo[1,2-a]pyridine as an anthelmintic

Jean-Paul Déto *et al.* [90] described a new series of imidazo[1,2-a] pyridine-based anthelmintic, showing an action on the parasitic nematode *Strongyle Haemonchus contortus*. One (compound **115**) of its compounds (Figure 23) , the most powerful inhibited the motility of worms at 31.25 μ M. In addition, an original mode of action was unveiled for this compound, since the observed paralysis was correlated with an antagonistic effect on the two Levaamisole – nAChR1 and two other subtypes.




Figure 23: Structure of 4-(4-chlorophenyl)-3-((6-(4-methylpiperazin-1-yl)*H*-imidazo[1,2-a]pyridin-2-yl)methyl)but-3-enitrile with anthelmintic activity

f. Imidazo[1,2-a]pyridine as an antileishmanial agent

Cyril Fersing et al. [91] showed that the 3-nitroimidazo[1,2-a]pyridine derivatives substituted in the 2-position by thiobenzyl have good antileishmanial activities. Indeed, the *in vitro* evaluation of these compounds showed that one of them (compound **116**) was a successful pest control.

This single molecule exhibited low cytotoxicity to human cell-line HepG2 ($CC_{50} > 100 \mu\text{M}$) showed good antileishmanial activity ($IC_{50} = 12.1 \mu\text{M}$) against *L. donovani*, *L. infantum*, and *L. major* and good antitrypanosomian activities ($IC_{50} = 1.3\text{-}2.2 \mu\text{M}$) against *T. brucei* and *T. cruzi*, in comparison with several reference drugs such as miltefosin, fexinidazole, eflornithine and benznidazole ($IC_{50} = 0.6\text{-}13.3 \mu\text{M}$).




Figure 24: Structure of 6-chloro-8-((4-chlorophenyl)thio)-3-nitro-2-((phenylsulfonyl)methyl)imidazo[1,2-a]pyridine

g. Imidazo[1,2-a]pyridine as anti-tuberculosis drug

Mycobacterium tuberculosis is a major human pathogen and the cause of lung disease.[92] Through the use of high-throughput whole cell screening from a library of extended compounds, a number of imidazo[1,2-a]pyridine were obtained as highly active molecules against *M. tuberculosis* and *Mycobacterium Bovis* BCG. Some of the imidazopyridine derivatives (compounds **117**, **118** and **119**) showed inhibitory diameters (MICs) in the 0.03 to 5 mm range against *Mycobacterium Bovis* strain.

Also, work by Garrett C. Moraski et al. on imidazopyridines, has led to antituberculosis compounds.[93] The 2,7-dimethylimidazo[1,2-a]pyridine-3-carboxamide derivatives (**120**, **121**) synthesized, were evaluated for their *in vitro* antituberculosis activities in comparison to the replication of resistant MTB strains. The synthesized imidazopyridine derivatives showed better anti-tuberculosis activities comparable to Nitroimidazole clinical candidate PA-82419 (CMIs versus MDR-TB of 0.03 to 0.25 $\mu\text{g/mL}$ or 0.08 to 0.7 μM , respectively) at concentrations below 1 μM .




Figure25: 2,7-dimethylimidazo[1,2-a]pyridine-3-carboxamides derivatives found as antituberculosis drugs

h. Imidazo[1,2-a]pyridine as a pest control

The pest control potency of imidazopyridine was assessed using *Trichomonas Vaginalis*. GT3 was a highly pathogenic strain isolated in the city of Guanajuato, Mexico in 2012 [94]. Margarita Lopez-Martinez et al. showed that most of the synthesized compounds got antiparasitic activity after 24 h of treatment. As a result, the results, the ethyl 3-nitroimidazo[1,2-a]pyridine-2-carboxylate (**122**) and the 3-nitroimidazo[1,2-a]pyridine (**123**) had good anti-parasitic activity, requiring 2.45–3.96 μM to reach the desired effect. They also correlate partition coefficient ($\log P$) determination and antiparasitic activity for all the tested. A mathematical descriptor correlating the exhibited pharmacological activity and $\log P$ was found ($0.9 \pm 0.3 \log P$), which suggests that an optimum balance between hydrophilic and lipophilic properties is most convenient. Calculations based on this equation show that 84% of the total activity variation found may be described by these two variables.




Figure 26: 3-nitro-imidazopyridine derivatives possessing antiparasitic activity

i. Imidazo[1,2-a]pyridine as an antifungal agent

Several synthetic imidazopyridine derivatives were evaluated for their *in vitro* antifungal activities against *Aspergillus fumigates* 3007 and *Candida albicans* 3018 [95]. The test on these strains of showed that all the prepared compounds inhibited the growth of fungi to different degrees. Among the prepared compounds, compound **126** had the highest inhibitory index of 52.12% after 96 h incubation, followed by compounds **124** and **125**, which showed with inhibitory index of 49.87 and 43.51%, respectively. The authors also investigated the effect of the synthetic compounds on the unicellular fungus *C. Albicans* 3018 after 24h incubation. These compounds were tested at concentrations ranging from 0.0976 to 100 $\mu\text{g/mL}$. Compound **126** was observed to have the lowest inhibitory concentration of 0.390 $\mu\text{g/mL}$. Compounds **125** and **126** completely inhibited fungal growth at a concentration of 0.781 $\mu\text{g/mL}$.




Figure 27: N-substitued- 2-aryl-imidazopyridine derivatives with antifungal activity

j. Imidazo[1,2-a]pyridine as an anti-inflammatory agent

Renata B. [96] analyzed *in vivo* assays of Nociception, hyperalgesia, inflammation and *in vitro* of human PGHS-2 inhibitory compounds. The study suggests that some of the compounds can inhibit significant edema formation. Three (**127,128,129**) of the prepared imidazopyridine derivatives exhibited excellent anti-inflammatory activity with an inhibition concentration of 8.7 Lmol/kg (3.4

mg/kg) compared to celecoxib, a selective PGHS-2 inhibitor ($IC_{50} = 2.8$ lumens), representing the standard anti-inflammatory drug (30% inhibition at 100 Lmol/kg).




Figure 28: Imidazo[1,2-a]pyridin-3-amine derivatives with anti-inflammatory activities

II-2. Methods of synthesis of the imidazopyridine scaffold

The imidazo[1,2-a]pyridine ring was first described by Chichibabin[97] in 1925 and for a long time, this framework was not fully studied, partly because of the lack of effective functional methods, structural variants, especially in the pyridine core. However, much work has been done on the synthesis, physical and reactivity properties of this ring for decades. In particular, advances in catalytic chemistry and metal coordination chemistry in particular have facilitate access to new functions. It should be noted that to carry out the synthesis of imidazo[1,2-a]pyridines, several methods are described in the literature. Of all the methods, two are the most famous. These include the condensation of 2-aminopyridine with α -halogenocarbonyls and the multi-component reaction between the same amino substrate itself and, a carbonyl compound and isonitrile compounds.

a. Synthesis from 2-aminopyridine with α -halognocarbonyl compounds

In 1961, W. L. Mosby was able to synthesize the imidazo[1,2-a]pyridine scaffold while modifying the Chichibabin method, [98] using 2-aminopyridine and bromoacetadehyde in refluxing hydrated ethanol in the presence of sodium bicarbonate (Figure 29a).

Also, Andrés A. Trabanco[99] *et al.* cycling between 2-bromo-4,4,4-trifluorobutanal and 2-amino-4-chloro-3-iodopyridine in ethanol in the absence of a base but in a microwave oven at 150°C. Substituted pyridine in position-3 with a good yield in 50 min which considerably reduces the reaction time. In 2013, Castera-Ducros *et al.* synthesized 2-chloromethylimidazopyridine derivatives in one-step with yields ranging from 40 to 70%.[100] For their part, they performed a cyclic condensation rection between the 2-aminopyridine and 1,3-dichloroacetone derivatives by refluxing in ethanol for 4 h.

Maxwellet *al.* [101] synthesized the imidazo[1,2-a]pyridine core substituted at the position-2 by a two-stage reactive halogen. First, 2-aminopyridine reacts with 2-chloroacetic acid in water in the presence of triethylamine at 90°C for 5 hours to obtain a reactive intermediate. The latter is treated again in the presence of POCl₃ in toluene at 115°C for 16 h to obtain the imidazo[1,2-a]pyridine core substituted with chlorine at the -2 position .

Replacement of the imidazo[1,2-a]pyridine scaffold at the 2-position with an ester group was achieved after condensation between 2-aminopyridine and refluxing ethyl bromopyruvate in ethanol. [102] This compound was obtained with a 70% return.

Chezal *et al.* [103] were able to synthesize imidazo[1,2-a]pyridine substituted in position 2 by aryl (benzyl and p-methoxybenzyl) and alkyl groups (terbutyl, isopropyl, methyl, trifluoromethyl) by condensing various α -halogenocarbonyls with derivatives of 2-aminopyridine.

6-bromo-2-(3,4-dichlorophenyl)-imidazo[1,2-a]pyridine was reported by Shankarrapa *et al.* [104] by microwave irradiation with a yield of 60%. This was achieved by addition of 5-bromo-2-aminopyridine and 2-bromo-1-(3,4-dichlorophenyl)ethanone in DMF, while microwave irradiation achieved 150°C for 10 minutes at a power of 200 Watts.

The solvent of this reaction can be replaced by cyclohexanone, but the reaction time increases at 18 hours and at a temperature of 130°C.[105]

This reaction was echoed by Dongjian Zhu *et al.* The work here consists of reacting derivatives of 2-aminopyridine with those of bromophenacyl at room temperature and without solvent. The method is the crushing of the two compounds in a mortar. They obtained derivatives of the imidazo[1,2-a]pyridine nucleus substituted in position -2 by aryl derivatives and in position -6 by methyl in a very short time with yields ranging from 90 to 95%. [106], [107]




Figure 29: a. Chichibabin method of imidazopyridine synthesis b. synthesis of 3-(2,2,2-trifluoroethyl) *H*-imidazo[1,2-*a*]pyridine according to Andrés A. Trabanco *et al.* c. Synthesis method of 2-chloromethyl imidazopyridine derivatives according to Caroline Castera-Ducros *et al.* d. Synthesis method of 2-chloroimidazopyridine according to Brad D. Maxwell *et al.* e. Synthesis method of ethyl *H*-imidazo[1,2-*a*]pyridine-2-carboxylate derivatives f. Synthesis method of 2-substituted imidazopyridine according to Chezal *et al.* g. Synthesis method of 2-(3,4-dichloro)-6-bromo imidazopyridine according to Shankarrapa *et al.* h. Synthesis method of 2-substituted imidazopyridine according to Dongjian Zhu.

b. Multicomponent synthesis

Multicomponent reactions are reactions that occur in one reaction step with at least three reagents. This procedure made it possible the synthesis of several rings with very interesting pharmacological properties.

Katrin Groebke *et al.* [108] obtained the substituted imidazopyridine core at the 2- and 3-positions, while reacting the 2-aminopyridine with aldehydes derivatives and isonitrile. This reaction was carried out in methanol at room temperature overnight. Adding a few drops of acetic acid speeds up the condensation reaction. Derivatives of Imidazo[1,2-a] pyridine are obtained with yields ranging from 38% to 90% In this same dynamic, Martina Hieke *et al.* adopted the same reaction for their work, but made sure to replace morpholine for benzaldehyde [109] (Figure 30.a)..

Recently, in 2020, the team of Carlos *et al.* [110] this time synthesized imidazo[1,2-a]pyridine from the condensation of 2-aminopyridine, tert-butylisonitrile and 3-formyl-chromone in ethanol in the presence of a few drops of ammonium chloride (Figure 30.b). This reaction takes place in a microwave at 80°C for 15 min. The yields obtained (23% to 36%) are lower than previously. Long before them, the work of Taleb *et al.* followed the same path to the synthesis of imidazopyridines. For their work, they reacted a derivative of 2-aminopyridine with aldehyde derivatives and isonitrile in a methanol-dichloromethane mixture in volume ratio (2:3). [111] This reaction occurred at room temperature for 12 hours in the presence of scandium triflate ($\text{Sc}(\text{OTf})_3$) as a catalyst (Figure 30.c).

Mehdi Adib *et al.* synthesized imidazo[1,2-a]pyridine derivatives substituted in position-2 by aryl compounds and in position-3 by amine function, while condensing a mixture of isocyanide, various aldehydes and derivatives of 2-aminopyridine [112] (Figure 30.d). The reaction is carried out in water at 70°C for 7 hours to obtain various imidazo[1,2-a]pyridine with yields ranging from 85% to 96%.

In 2012, Anneli Nordqvist *et al.* [113] used this method while changing reaction conditions (Figure 30.e). They react aldehyde derivatives, isocyanide and 2-amino-5-bromopyridine in the presence of magnesium chloride (MgCl_2) in ethanol for 20 to 30 min in a microwave oven at 160°C. They obtained imidazo[1,2-a]pyridine derivatives substituted in position-2 by aryl compounds and in position -3 by amine function with a yield of 56%.

Ping Liu *et al.* developed a novel tri-component reaction synthesizing of imidazo[1,2-a]pyridine derivatives using 2-aminopyridine derivatives, aldehyde, and alkyne [114]. After 18 h of reflux in toluene, in the presence of catalyst such as copper sulfate (CuSO_4) and 4-methylbenzenesulfonic acid (Figure 30.f), imidazo[1,2-a]pyridine derivatives are obtained with yields ranging from 28% to 68%.

Pushpalatha B. *et al.* [80] synthesized imidazo[1,2- a]pyridine from 4-methyl acetophenone, 2-amino-5-methyl pyridine and dibromine (Br_2) in methanol in the presence of Lewis acid (AlCl_3). This reaction (Figure 30.g) occurred between 0 and 5°C with a 57% yield.




Figure 30: **a.** Synthesis method of imidazopyridine via multi components pathway according to Martna Hieke. **b.** Synthesis method of the 2-substituted imidazopyridine by the multicomponent pathway according to Katrin Groebke *et al.* **c.** Zarate-Hernández *et al.* synthesis method of imidazopyridine substituted N-derivatives **d.** synthesis of imidazopyridine substituted N-substitutes multicomponent according to Mehdi Adib *et al.* **e.** method of synthesis of imidazopyridine substituted N-substitutes multicomponent according to Anneli Nordqvist *et al.* **f.** Synthesis method of 2,3-disubstituted imidazopyridine via multi-component

pathway according to Ping Liu *et al.* **g.** Pushpalatha Budumuru multi-component synthesis method of the derivatives of 2-phenyl imidazopyridine

c. Synthesis from nitroolefins

The synthesis of the imidazo[1,2-a]pyridine core from the nitroolefins allowed to activate it in position 3 with the nitro group. Most of these reactions occur in the presence of a catalyst.

Prashant B. Jagadhane *et al.* [115] were able to synthesize the imidazo[1,2-a]pyridine core by reacting 1-(2-nitrovinyl)benzene with 2-aminopyridine in the presence of sodium dichloriodide (NaI₂) in the DMF at 80°C for 1 hour and 30 minutes (Figure 31.a).

This reaction was carried out in several solvents such as dimethylsulfoxide (DMSO), methanol (MeOH), ethanol (EtOH) and acetonitrile (CH₃CN). However, using only dimethylformamide (DMF) as a solvent resulted in better yields of 65 to 85%.

This method was developed by Litao An *et al.* [116]. Using the same reagents, they reacted in acetonitrile (CH₃CN) as a solvent with another catalyst, iodine-*tert*-butylhydroperoxide-pyridine (TBHP-Py) to obtain the imidazopyridine core in 36 to 90% yields (Figure 31.a).. The replacement of the catalyst made it possible to increase the reaction time (12h vs. 1h30).




Figure 31: a.Synthesis method of 3-nitro-2-phenyl-imidazopyridine derivatives according to Prashant B. Jagadhane *et al.* b.Synthesis method of 3-nitro-2-phenyl-imidazopyridine derivatives according to Litao An *et al.*

d. Synthesis from α -chloro- β -diketone

In our group, Ouattara *et al.* [85] were able to synthesize 3-acetyl-2-methylimidazo[1,2-a]pyridine by the reaction of 2-aminopyridine and 3-chloro-penta-2,4-dione after a reflux heterocyclic reaction in ethanol (Figure 32). This method resulted in a ketone function at the -3 position of the imidazo[1,2-a]pyridine core.




Figure 32: Synthesis method of 1-(2-methylH-imidazo[1,2-a]pyridin-3-yl)ethanone via an α -chloro- β -diketone

e. Synthesis from a pyridinium salt

A synthetic route for imidazopyridine derivatives was identified by Juan A. Vega et al. [117] from pyridinium salt. In their research, two synthetic lines were identified. The first route is the synthesis of 2-amino imidazo[1,2-a]pyridine derivatives by reaction of 1-alkyl-2-chloropyridinium salt derivatives with reflux cyanamide (H_2NCN) in acetonitrile in the presence of potassium carbonate (K_2CO_3) for 13-20 hours with a return of 65-70% (Figure 33.a).

For the second synthetic pathway, they obtained the 2-amino imidazo[1,2-a]pyridine derivatives in two steps. First, by converting 1-alkyl-2-chloropyridinium salt into 2-ylidencyanamidopyridine. Secondly, after this transformation, the latter was treated, in the presence of LDA in tetrahydrofuran (THF) for 6 to 24 h at room temperature to finally obtain the 2-amino imidazo[1,2-a]pyridine derivatives. We noted that the best yields were obtained from this last synthesis route (figure 33.b).

Similarly, H. Zali-Boeini et al. [118] synthesized 2,3-disubstitued imidazo[1,2-a]pyridine derivatives, by reaction of N-alkyl pyridinium with S-alkyl thiouronium salt derivatives in water at 75°C for 4 h in the presence of sodium hydrogen carbonate (NaHCO_3) (Figure 33.c).




Figure 33: **a.** Synthesis method of 2-aminoimidazopyridine derivatives from pyridinium salt according to Juan A. Vega et al. **b.** Synthesis method of 2-aminoimidazopyridine derivatives from pyridinium salt according to Juan A. Vega in two steps. **c.** Synthesis method of 2-aminoimidazopyridine derivatives from pyridinium salt according to Zali-Beoini

f. Synthesis from N-oxides

The 2-substituted imidazo[1,2-a]pyridine nucleus was developed by Eric Talbot et al. from 2-aminopyridine N-oxide. [119] They react with trifluoroacetic acid and gold dichloro-2-pyridinecarboxylate (PicAuCl₂) as catalysts, alkynes and 2-aminopyridine N-oxide at 40°C overnight in dichloromethane (DCM) as a solvent. After treatment of the reaction medium, the derivatives of the 2-substituted imidazo[1,2-a]pyridine are obtained with yields of 16 to 78 %.




Figure 34 : Synthesis method of 2-phenyl imidazopyridine derivatives from N-oxides

Perspectives

Antimicrobial resistance is one of the world's greatest public health threats today. Most antibiotics lose their effectiveness over time due to the virulence of toxins secreted by bacteria in defense, which leads to flare-ups of hospital-acquired disease. Another urgency is the widespread emergence of drug-resistant strains Methicillin (MRSA)-resistant *Staphylococcus aureus* (*S.*

aureus). [120] The death toll from MRSA turned out to be even higher. The rapid emergence of *S. aureus* strains resistant to HIV, [121] vancomycin [122], often considered the treatment of last resort, adds to the urgency of being able to access other active ingredients. As a result, there is an urgent need to develop new antibacterial agents that can overcome bacterial resistance, but much more emphasis on bacterial translocation proteins. Structural modification strategies of antibiotics with evolved resistance as an effective means of extending antimicrobial longevity are beginning to show their limitations. Multiple compound therapy has many potential benefits, including increased potency, reduced dosage or toxicity, and protection against development of drug resistance. This area is of increasing interest to scientists due to the enormous (un- or mis-)explored prospects for novel therapeutics. The development is partly guided by a biological systems perspective recognizing that many cellular processes are difficult to control using a single drug compound, and in part by screening multiple compounds. It is guided by high-performance computing instruments that make it quick and inexpensive. For example, when studying combinations of compounds in cancer chemotherapy, clinical evaluation of the benefits of combinations is relatively straightforward. Combinations are preferred if they have acceptable side effects and prolong long-term survival compared to alternative therapies. Therefore, the importance of developing new types of antibacterial agents, especially those with new mechanisms of action. Refocusing antimicrobial drug research on bacterial secretion pathways could be a big win. Therefore, SecA, a key protein in the bacterial secretory pathway, has been investigated as a target for the development of antibacterial agents. Synthesis and biological activity of various compounds derived from the combination of antimicrobial pharmacophores (aminopyrimidines and benzimidazoles) discussed in this review to form a potential SecA-inhibiting benzimidazolylaminopyrimidine motif. Our suggest research on both scaffold aminopyrimidine derivatives have many bioactivities, including bactericidal action and SecA inhibitors. In addition, these compounds also contain a benzimidazole core, whose antibacterial activity is shown and demonstrated here. An analysis of this literature concluded that pyrimidines substituted with electron-withdrawing groups such as nitro on phenyl have stronger antibacterial activity *in vitro* than chlorine atoms or methoxy groups. Nitro-substituted benzimidazolylaminopyrimidines can be excellent active ingredients. Humans have no homologues of the SecA, so these new compounds probably do not pose inherent toxicity problems. Selectively targeting SecA, which has no human counterpart, seems appropriate. Furthermore, SecA is present in all bacteria, making these new

antibacterial agents effective against a broad spectrum of bacteria. After extensive review of the medicinal chemistry literature for both pharmacophores, we could find a potential drug against bacteria. This study addresses the following questions: how can we effectively overcome drug resistance in bacteria? Is addition of pharmacophore will enhance the potency? Is the the best target is translocation of protein.

Conclusion

In this review article, we attempt to summarize several biological activities and synthetic routes for the synthesis of both heterocyclic benzimidazole and imidazo[1,2-a]pyridine compounds. The presence of certain substituents in their derivatives indicates that they can be used as pharmacologically molecules or drugs intermediates. Our point of view in perspectives showed how we would like to currently investigate the combination of both pharmacophore in this research.

Conflict of interest

The authors confirm that this article has no conflict of interest.

References

- [1] Blair J. M. A., Webber M. A., Baylay A. J., Ogbolu D. O., et Piddock L. J. V., « Molecular mechanisms of antibiotic resistance », *Nature Reviews Microbiology*, vol. 13, n° 1, p. 42-51, janv. 2015, doi: 10.1038/nrmicro3380.
- [2] Organisation mondiale de la Santé, « Rapport sur la tuberculose dans le monde 2020 : résumé d'orientation », 2020.
- [3] Sumit T., Kalavathy R., Siong M. L., Syeed A. A. S., Vasudevan M., et Balasubramanian N., « 4-(2-(1H-Benzo[d]imidazol-2-ylthio)acetamido)-N-(substituted phenyl)benzamides: design, synthesis and biological evaluation », *BMC Chemistry*, vol. 13, n° 1, p. 12, déc. 2019, doi: 10.1186/s13065-019-0533-7
- [4] Ulviye A. C., Begum N. S., Serkan L., Derya O., Betul K. C., Yusuf O. et Zafer A. K., « Synthesis and AChE-Inhibitory Activity of New Benzimidazole Derivatives », *Molecules*, vol. 24, n° 5, p. 861, févr. 2019, doi: 10.3390/molecules24050861.
- [5] Sumit T., Sanjiv K. et Balasubramanian. N., « Antimicrobial potential of 1H-benzo[d]imidazole scaffold: a review », *BMC Chemistry*, vol. 13, n° 1, p. 18, déc. 2019, doi: 10.1186/s13065-019-0521-y.
- [6] Ratika S., Alka B., et Bahadur B C., « Synthesis of methanesulphonamido-benzimidazole derivatives as gastro-sparing antiinflammatory agents with antioxidant effect », *Bioorganic & Medicinal Chemistry Letters*, vol. 27, n° 13, p. 3007-3013, juill. 2017, doi: 10.1016/j.bmcl.2017.05.017.
- [7] Terence N. O., Latyfa E. O., Mostafa E. G., Redouane A., Hind C., Meryem E. J., Yahia C., Katim A. et Amina Z., « Synthesis of Surfactants Derived from 2-Mercaptobenzimidazole and Study of Their Acute Toxicity and Analgesic and Psychotropic Activities », *Biochemistry Research International*, vol. 2019, p. 1-9, juill. 2019, doi: 10.1155/2019/9615728.
- [8] Tonelli M., Paglietti G., Boido V., Sparatore F., Marongiu E., La Colla P. et Loddo R., « Antiviral Activity of Benzimidazole Derivatives. I. Antiviral Activity of 1-Substituted-2-

[(Benzotriazol-1/2-yl)methyl]benzimidazoles », *Chemistry & Biodiversity*, vol. 5, n° 11, p. 2386-2401, nov. 2008, doi: 10.1002/cbdv.200890203.

- [9] Paulina F. C., José M. V. L., Rodrigo A. O., Alicia H. C., Pedro J. T. S., Lilian Y. M. et Raphael C., « Synthesis, antiprotozoal activity, and chemoinformatic analysis of 2-(methylthio)-1 H - benzimidazole-5-carboxamide derivatives: Identification of new selective giardicidal and trichomonocidal compounds », *European Journal of Medicinal Chemistry*, vol. 137, p. 211-220, sept. 2017, doi: 10.1016/j.ejmech.2017.05.058.
- [10] John O., Christel B., Kawaljit S., Godwin A.D., Linley B., Mathew N., Sergio W. et Kelly C., « Antimalarial Pyrido[1,2- a]benzimidazole Derivatives with Mannich Base Side Chains: Synthesis, Pharmacological Evaluation, and Reactive Metabolite Trapping Studies », *ACS Infectious Diseases*, vol. 5, n° 3, p. 372-384, mars 2019, doi: 10.1021/acsinfecdis.8b00279.
- [11] Michele T., Elene G., Francesca P., Nicoletta B., Silvia P., Bruno T., Roberta L., Fabio S. et Anna S., « Benzimidazole derivatives endowed with potent antileishmanial activity », *Journal of Enzyme Inhibition and Medicinal Chemistry*, vol. 33, n° 1, p. 210-226, janv. 2018, doi: 10.1080/14756366.2017.1410480.
- [12] Amanda L. R., Pulane M. et Christopher J. P., « Multicomponent synthesis of imidazo[1,2- a]pyridines using catalytic zinc chloride », *Tetrahedron Letters*, vol. 48, p. 4079-4082, 2007.
- [13] Bagdi A. K., Santra S., Monir K., et Hajra A., « Synthesis of imidazo[1,2-a]pyridines: a decade update », *Chemical Communications*, vol. 51, n° 9, p. 1555-1575, 2015, doi: 10.1039/C4CC08495K.
- [14] Assessment report, « For Zolpidem-containing medicinal products », *European Medicines Agency*, p. 1-18, avr. 24, 2014.
- [15] Cécile E. G. et Alain G., « Recent Progress in the Pharmacology of Imidazo[1,2-a]pyridines », *Mini-Reviews in Medicinal Chemistry*, vol. 7, n° 9, p. 888-899, 2007
- [16] Vidyacharan S., Shinde A. H., Satpathi B., et Sharada D. S., « A facile protocol for the synthesis of 3-aminoimidazo-fused heterocycles via the Groebke–Blackburn–Bienayme

reaction under catalyst-free and solvent-free conditions », *Green Chemical*, vol. 16, n° 3, p. 1168, 2014, doi: 10.1039/c3gc42130a.

[17] Liu H.B., Gao W.W., Tangadanchu V.K.R., Zhou C.H., et Geng R.X., « Novel aminopyrimidinyl benzimidazoles as potentially antimicrobial agents: Design, synthesis and biological evaluation », *European Journal of Medicinal Chemistry*, n° 143, p. 63-84, 2018.

[18] Zhou M., Eun Y.J., Guzei I.A. et Weibel D.B., « Structure–activity studies of divin: An inhibitor of bacterial cell division », *Medicinal Chemistry Letters*, n° 4, p. 880-885, 2013.

[19] Ramya V. S., Kallappa M. H., et Rangappa S. K., « Synthesis and evaluation of in vitro anti-microbial and anti-tubercular activity of 2-styryl benzimidazoles », *European Journal of Medicinal Chemistry*, vol. 44, p. 4244-4248, 2009.

[20] Muayed A. R., Baqir W. A., et Mudhafar A. M., « Synthesis, Characterization and Antibacterial Evaluation of some Novel Benzimidazole Derivatives Containing 1,3,4-Thiadiazole Moiety. », *Oriental Journal of Chemistry*, vol. 33, n° 6, p. 3138-3143, déc. 2017, doi: 10.13005/ojc/330656.

[21] Andrea B., Luka K., Ivana S., Domagoji D., Jasminka T., Martin C. T., John M. K., Miroslav B. et Silvana R. M., « Synthesis, anti-bacterial and anti-protozoal activities of amidinobenzimidazole derivatives and their interactions with DNA and RNA », *Journal of Enzyme Inhibition and Medicinal Chemistry*, vol. 33, n° 1, p. 1323-1334, janv. 2018, doi: 10.1080/14756366.2018.1484733.

[22] Woolley D. W., « some biological effects produced by benzimidazole and their reversal by purines », *Journal of Biological Chemistry*, vol. 152, n° 2, p. 225-232, févr. 1944, doi: 10.1016/S0021-9258(18)72045-0.

[23] Maertens J. A., « History of the development of azole derivatives », *Clinical Microbiology and Infection*, vol. 10, p. 1-10, 2004, doi: 10.1111/j.1470-9465.2004.00841.x.

[24] Mishra L., V. Singh K., Dubey N. K., et Mishra A. K., « Synthesis and Fungicidal Activity of Some 5-Membered Heterocyclic Derivatives Containing Benzimidazoles », *Bioscience*,

Biotechnology, and Biochemistry, vol. 57, n° 6, p. 989-991, janv. 1993, doi: 10.1271/bbb.57.989.

- [25] Gulgun A. K. et Nurten A., « Synthesis and Antifungal Properties of Some Benzimidazole Derivatives », *Journal of Chemica Turkey*, vol. 30, p. 223-228, 2006.
- [26] Hakan G., Canan K., David W. B., Sulhiye Y. et Nurten A., « Synthesis of Some New 2-Substituted-phenyl-1H-benzimidazole- 5-carbonitriles and Their Potent Activity Against Candida Species », *Bioorganic & Medicinal Chemistry*, vol. 10, p. 2589-2596, 2002.
- [27] Cheong J.E., Zaffagni M., Chung I., Xu Y., Wang Y., Jernigan F.E., Zetter B.R., et Sun L., « Synthesis and anticancer activity of novel water soluble benzimidazole carbamates », *European Journal of Medicinal Chemistry*, n° 144, p. 372-385, 2018.
- [28] Ibrahim H.A., Awadallah F.M., Refaat H.M., et Amin K.M., « Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted- 5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met », *Bioorganic Chemistry*, n° 77, p. 457-470, 2018.
- [29] Refaat H. M., « Synthesis and anticancer activity of some novel 2-substituted benzimidazole derivatives », *European Journal of Medicinal Chemistry*, vol. 45, n° 7, p. 2949-2956, juill. 2010, doi: 10.1016/j.ejmech.2010.03.022.
- [30] Salahuddin M. S., Mazumder A., et Ahsan M. J., « Synthesis, characterization and anticancer evaluation of 2-(naphthalen-1-ylmethyl/naphthalen-2-yloxymethyl)-1-[5-(substituted phenyl)-[1,3,4]oxadiazol-2-ylmethyl]-1H-benzimidazole », *Arabian Journal of Chemistry*, vol. 7, n° 4, p. 418-424, sept. 2014, doi: 10.1016/j.arabjc.2013.02.001.
- [31] Abdel-Mohsen H. T., Ragab F. A. F., Ramla M. M., et El Diwani H. I., « Novel benzimidazole-pyrimidine conjugates as potent antitumor agents », *European Journal of Medicinal Chemistry*, vol. 45, n° 6, p. 2336-2344, juin 2010, doi: 10.1016/j.ejmech.2010.02.011.
- [32] Márquez-Navarro A., Noguera-torres B., Hernandez-campos A., Soria-arteche O., Castillo R, Rodriguez-Morales S., Yépez-Mulia L., Hernandez-luis F., « Anthelmintic activity of

benzimidazole derivatives against *Toxocara canis* second-stage larvae and *Hymenolepis nana* adults », *Acta Tropica*, vol. 109, n° 3, p. 232-235, mars 2009, doi: 10.1016/j.actatropica.2008.11.014.

[33] Prasada R. C. M. M., Lakshmi A. J., Mani Y. G., Sudha B. S., Rekha P. B., Satyaprakash K., et Dhachinamoorthi D., « in vitro anthelmintic activity of novel benzimidazole derivatives from o-phenylene diamine », *World Journal Of Pharmaceutical And Medical Research*, vol. 4, n° 4, p. 245-248, 2018.

[34] Faruk A., Biplab K. D., Kamal S., Arpita C. et Pallab K., « synthesis, antimicrobial and anthelmintic activity of some novel benzimidazole derivatives », *International Journal of Drug Research and Technology*, vol. 4, n° 3, p. 31-38, 2014.

[35] Mavrova A. T., Kamelya K. A., Dimitar I. V., Jordan A. T., Pavletta S. D., Magdalena S. K. et Mitka K. M., « Antihelminthic activity of some newly synthesized 5(6)-(un)substituted-1H-benzimidazol-2-ylthioacetylpiperazine derivatives », *European Journal of Medicinal Chemistry*, vol. 41, n° 12, p. 1412-1420, déc. 2006, doi: 10.1016/j.ejmech.2006.07.005.

[36] Mavrova A. T., Kamelya K. A., Dimitar I. V., Jordan A. T., Pavletta S. D., Magdalena S. K. et Mitka K. M., « Antihelminthic activity of some newly synthesized 5(6)-(un)substituted-1H-benzimidazol-2-ylthioacetylpiperazine derivatives », *European Journal of Medicinal Chemistry*, vol. 41, n° 12, p. 1412-1420, déc. 2006, doi: 10.1016/j.ejmech.2006.07.005.

[37] Vitale G., Corona P., Loriga M., Carta A., Paglietti G., Ibba C., Giliberti, G., Loddo R., Marongiu E., La Colla P., « Styrylbenzimidazoles. Synthesis and biological activity—Part 3 », *Medicinal Chemistry*, n° 6, p. 70-78, 2010.

[38] Barreca M. L., Rao A., Luca De L., Iraci N., Monforte A. M., Maga G., Clercq De E., Pannecouque C., Balzarini J., Chimirri A., « Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains », *Bioorganic & Medicinal Chemistry Letters*, vol. 17, n° 7, p. 1956-1960, avr. 2007, doi: 10.1016/j.bmcl.2007.01.025.

- [39] Laura G., Erik De C., et Marinella R., « Synthesis and Antiviral/Antiproliferative Activity of Some N-Sulphonylbenzimidazoles », *Bioorganic & Medicinal Chemistry Letters*, vol. 12, p. 2707-2710, 2002.
- [40] Deepika S., Balasubramanian N., Pradeep K., Vikramjeet J., Rakesh N., Erik De C. et Jan B., « Synthesis, antimicrobial and antiviral activity of substituted benzimidazoles », *Journal of Enzyme Inhibition and Medicinal Chemistry*, vol. 24, n° 5, p. 1161-1168, oct. 2009, doi: 10.1080/14756360802694427.
- [41] Achar K.C.S., Hosamani, K.M. et Seetharamareddy H.R., « In vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives », *European Journal of Medicinal*, n° 45, p. 2048-2054, 2010.
- [42] Iemura R., Kawashima T., Fukuda T., Ito K. et Tsukamoto G., « Synthesis of 2-(4-substituted 1-piperazinyl) benzimidazoles as H1-antihistaminic agents. », *Journal of Medicinal Chemistry*, n° 29, p. 1178-1183, 1986.
- [43] Monika G., Sarbjot S., et Chander M., « Benzimidazole: An emerging scaffold for analgesic and anti-inflammatory agents », *European Journal of Medicinal Chemistry*, vol. 76, p. 494-505, 2014.
- [44] Kavitha C.S. A., Kallappa M. H., et Harisha R. S., « In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives », *European Journal of Medicinal Chemistry*, vol. 45, p. 2048-2054, 2010.
- [45] Thimme G. N. R., Kavitha C. V., Kishore K. C., Omana J., Kanchugarakoppal S. R. et Sathees C. R., « Synthesis and biological evaluation of novel 1-(4-methoxyphenethyl)-1Hbenzimidazole-5-carboxylic acid derivatives and their precursors as antileukemic agents », *Bioorganic & Medicinal Chemistry Letters*, vol. 19, p. 4594-4600, 2009.
- [46] Mahama O., Drissa S., William Y. et Mamidou W. K., « Synthèse et criblage antiplasmodial de quelques benzimidazolyl-chalcones », *International Journal of Biological Chemical Sciences*, vol. 9, n° 3, p. 1697-1710, 2015.

- [47] Bandyopadhyay P., Manisha S., Sachin N. T., Ruchi Y., Pratibha S., Ashok K. et Kaushik M. P., « Synthesis of some novel phosphorylated and thiophosphorylated benzimidazoles and benzothiazoles and their evaluation for larvicidal potential to *Aedes albopictus* and *Culex quinquefasciatus* », *Bioorganic & Medicinal Chemistry Letters*, vol. 24, n° 13, p. 2934-2939, juill. 2014, doi: 10.1016/j.bmcl.2014.04.082.
- [48] José C., Arthur B., Neira G., Juan R., Rosario R., Abraham V., Robert G. et Jaime C., « Synthesis and biological evaluation of benzimidazole-5-carbohydrazide derivatives as antimalarial, cytotoxic and antitubercular agents », *Bioorganic & Medicinal Chemistry*, vol. 19, p. 2023-2029, 2011.
- [49] Divatia S. M., Rajani D. P., Rajani S. D., et Patel H. D., « Novel thiosemicarbazone derivatives containing benzimidazole moiety: Green synthesis and anti-malarial activity », *Arabian Journal of Chemistry*, vol. 12, n° 7, p. 1641-1651, nov. 2019, doi: 10.1016/j.arabjc.2014.09.007.
- [50] Toro P., Hugo A. K., Bruno P., Lahoz F., Pascual A., Biot C. et Arancibia R., « Organometallic benzimidazoles: Synthesis, characterization and antimalarial activity », *Inorganic Chemistry Communications*, vol. 35, p. 126-129, sept. 2013, doi: 10.1016/j.inoche.2013.06.019.
- [51] Sarika S., Dhiman N., Aman M. et Gaurav K., « Synthesis And Antioxidant Activity Of The 2-Methyl Benzimidazole », *Journal of Drug Delivery and Therapeutics*, vol. 6, n° 3, p. 100-102, 2016.
- [52] Dvornikova I. A., Buravlev E. V., Fedorova I. V., Shevchenko O. G., Chukicheva I. Yu., and Kutchin A. V. « Synthesis and antioxidant properties of benzimidazole derivatives with isobornylphenol fragments » *Russian Chemical Bulletin, International Edition*, Vol. 68, No. 5, pp. 1000—1005, May, 2019
- [53] Sabrina R. A., Biplab K. D., MD Shahadat H., Uttom K. and Abu S. S. R., «Synthesis and antioxidant activity of 2-substituted-5-nitro benzimidazole derivatives». *International Journal of Pharmacy and Pharmaceutical Sciences*; vol 9, No 1, pp.308-310, 2017

- [54] Hobrecker F. "Reduction-products of nitracetamide compounds" *Deut. Chem. Ges. Ber.*, vol. 5, p. 920-924, 1872.
- [55] Montague L. I., « CCCXVII.-The Formation of 2-substituted Benzimidazoles. », *Journal of the Chemical Society*, p. 2393-2399, 1928.
- [56] El-Gohary N. S. et Shaaban M. I., « Synthesis, antimicrobial, antiquorum-sensing and antitumor activities of new benzimidazole analogs », *European Journal of Medicinal Chemistry*, vol. 137, p. 439-449, sept. 2017, doi: 10.1016/j.ejmech.2017.05.064.
- [57] Odame F., Hosten E., Betz R., Lobb K. et Tshentu Z. R., « Benzimidazole or Diamide From a Reaction of Diamines and Carboxylic Acids or Acid Chlorides: Crystal Structures and Theoretical Studies », *Acta Chimica Slovenica*, p. 986-994, déc. 2015, doi: 10.17344/acsi.2015.1703.
- [58] Kiumars B., Mohammad M. K. et Iman K., « H₂O₂/HCl as a new and efficient system for synthesis of 2-substituted benzimidazoles », *Journal of Chemical Research*, p. 783-784, 2006.
- [59] K. Bahrami, M. Khodaei, et I. Kavianinia, « A Simple and Efficient One-Pot Synthesis of 2-Substituted Benzimidazoles », *Synthesis*, vol. 2007, n° 04, p. 547-550, févr. 2007, doi: 10.1055/s-2007-965878.
- [60] K. Bahrami, M. Khodaei, et I. Kavianinia, « A Simple and Efficient One-Pot Synthesis of 2-Substituted Benzimidazoles », *Synthesis*, vol. 2007, n° 04, p. 547-550, févr. 2007, doi: 10.1055/s-2007-965878.
- [61] Du L.-H. et Wang Y.-G., « A Rapid and Efficient Synthesis of Benzimidazoles Using Hypervalent Iodine as Oxidant », *Synthesis*, vol. 2007, n° 5, p. 675-678, mars 2007, doi: 10.1055/s-2007-965922.
- [62] Karthikeyan C., Solomon V. R., Lee H., et Trivedi P., « Synthesis and biological evaluation of 2-(phenyl)-3H-benzo[d]imidazole-5-carboxylic acids and its methyl esters as potent anti-breast cancer agents », *Arabian Journal of Chemistry*, vol. 10, p. S1788-S1794, mai 2017, doi: 10.1016/j.arabjc.2013.07.003.

- [63] Sharghi H., Mashhadi E., Aberi M., et Aboonajmi J., « Synthesis of novel benzimidazoles and benzothiazoles via furan-2-carboxaldehydes, *o*-phenylenediamines, and 2-aminothiophenol using Cu(II) Schiff-base@SiO₂ as a nanocatalyst », *Applied Organometallic Chemistry*, vol. 35, n° 9, sept. 2021, doi: 10.1002/aoc.6330.
- [64] Alloum B. A., Bougrin K. et Soufiaoui M., « Synthèse chimiosélective des benzimidazoles sur silice traitée par le chlorure du thionyle », *Tetrahedron Letters*, vol. 44, p. 5935-5937, 2003
- [65] Duvuapally M., Sadhu P., et Punniyamurthy T., « Copper(II)-Catalyzed Oxidative Cross-Coupling of Anilines, Primary Alkyl Amines, and Sodium Azide Using TBHP: A Route to 2-Substituted Benzimidazoles », *Journal of Organic Chemistry*, vol. 81, n° 8, p. 3227-3234, avr. 2016, doi: 10.1021/acs.joc.6b00186.
- [66] Y. Kim, M. R. Kumar, N. Park, Y. Heo, et S. Lee, « Copper-Catalyzed, One-Pot, Three-Component Synthesis of Benzimidazoles by Condensation and C–N Bond Formation », *Journal of Organic Chemistry*, vol. 76, n° 23, p. 9577-9583, déc. 2011, doi: 10.1021/jo2019416.
- [67] Thanh. B. N., Bescont J. L., Ermolenko L., et Al-Mourabit A., « Cobalt- and Iron-Catalyzed Redox Condensation of *o*-Substituted Nitrobenzenes with Alkylamines: A Step- and Redox-Economical Synthesis of Diazaheterocycles », *Organic Letters*, vol. 15, n° 24, p. 6218-6221, déc. 2013, doi: 10.1021/ol403064z.
- [68] Hobrecker F., « Ueber Reductionaproducte der Nitracetamidverbindungen », *Berichte Dtsch. Chem. Ges.*, vol. 5, n° 2, p. 920-924, 1872.
- [69] Deepak B. N. et Bhalchandra M. B., « N-Substituted Formamides as C1-Sources for the Synthesis of Benzimidazole and Benzothiazole Derivatives by Using Zinc Catalysts », *SYNLETT Accounts and Rapid Communications in Chemical Synthesis*, vol. 26, p. 2835-2842, 2015, doi: 10.1055/s-0035-1560319.
- [70] Sissouma D., Adjou A., Touré S. A., Zoakouma S., Gnon B., et Téa G. C., Reactivity of Amidinium Salts' Access to Benzo[4,5]imidazo[2,1-b]Thiazoles , *Phosphorus, Sulfur, and*

Silicon and the Related Elements, vol. 180, n° 5-6, p. 1375-1378, mars 2005, doi: 10.1080/10426500590910620.

- [71] Timotou A., Adjou A., Say M. V., Sissouma D., Toure S., Tea G. C. et N'Guessan Y.T., Novel synthesis of benzimidazole by Ring Contraction Rearrangement of benzodiazepine, *International Journal of Biological and Chemical Sciences*, vol. 7, n° 6, p. 2568, mai 2014, doi: 10.4314/ijbcs.v7i6.31.
- [72] Camara T. E., Coulibali S., Kone S., Adeyole T., et Adjou A., « novel synthesis of 2-substituted benzimidazole by ring contraction rearrangement of 1, 5- benzodiazepines », *World Journal of Pharmaceutical Research*, vol. 7, n° 1, p. 61-84, 2017, doi: 10.20959/wjpr20181-10512.
- [73] Denise M., Philippe N., Jean-Michel L. Loubna L., Abdeslam E. A., Brahim L., El Mokhtar E., Bouziane B., et Abdelkhalek B., « Synthesis and structural study of N-isopropenylbenzimidazolone », *Russian Journal of Physical Chemistry*, vol. 89, n° 5, p. 807-811, 2015, doi: 10.1134/S0036024415050271.
- [74] Vakhid A. M., Nataliya A. Z., et Oleg G. S., « Advances in the synthesis of benzimidazolones via rearrangements of benzodiazepinones and quinoxalin(on)es », *Mendeleev Communications*, vol. 27, p. 1-11, 2017, doi: 10.1016/j.mencom.2017.01.001.
- [75] Leonard N. J., David Y.C. et Karl M. B., « Sulfonate Salts of Substituted Benzimidazoles1 », *Journal American Chemical Society*, vol. 69, n° 10, p. 2459-2461, 1947.
- [76] Hunger A., Kebrle J., Rossi A. et Hoffmann K., « Benzimidazol-Derivate und verwandte Heterocyclen III Synthese von 1-Aminoalkyl-2-benzyl-nitro-benzimidazolen », *Helvetica Chimica Acta*, vol. 43, n° 4, p. 1032-106.
- [77] Bhattacharaya S. C., « Synthesis and Characterization of Impurities of an Broad-spectrum Anthelmintic Drug, Albendazole », *Chemical Science Transactions*, vol. 5, 2016.
- [78] Asmaa S., Nada K. S., El Mokhtar E., « Synthese, Reactivite et Activités Biologiques des Dérivés du Benzimidazole », *Moroccan Journal of Heterocyclic Chemistry*, vol. 18, n° 3, p. 1-50, 2019.

- [79] Van Allan J. A. et Deacon B. D., « 2-mercaptobenzimidazole », *Organic. Synthetis*, vol. 30, p. 56, 1950, doi: 10.15227/orgsyn.030.0056.
- [80] Pushpalatha B., Srinivasarao G., Venkata S. S. K., Design and synthesis of novel imidazo[1,2-a]pyridine derivatives and their anti-bacterial activity, *Asian Journal of Pharmaceutical Clinical Research*, vol. 11, n° 8, p. 252-258, mai 2018, doi: <http://dx.doi.org/10.22159/ajpcr.2018.v11i8.26241>.
- [81] Kai. L., Linhu L., Wang B., Mingliang L., Wang B., Weiyi S., Huiyuan G., Yu L., Design, synthesis and antimycobacterial activity of novel imidazo[1,2- a]pyridine-3-carboxamide derivatives, *European Journal of Medicinal Chemistry*, vol. 137, p. 117-125, sept. 2017, doi: 10.1016/j.ejmech.2017.05.044.
- [82] Akram M.H. A., Mohammed A. A. et Saeb H. A., Imidazo[1,2-a]pyridine Based Compounds :The Hope ful Anti-Cancer Therapy, *Systematic Review Pharmacy*, vol. 12, n° 4, p. 79-85, 2021.
- [83] Gui-Ting S., Nicholas McC., Zhong-Zhu C., Xiao-Fang Y., Jiu-Hong H., Jie L., Hui-kuan L., Brendan F., Hong-yu L. et Zhi-Gang X., Diversity-Oriented Synthesis of Functionalized Imidazopyridine Analogues with Anti-Cancer Activity through a Transition-Metal Free, One-pot Cascade Reaction, *Advanced Synthesis & Catalysis*, vol. 360, n° 19, p. 3655-3661, oct. 2018, doi: 10.1002/adsc.201800728.
- [84] Nurit D. F., Candice L., Amanda L. R., Dharmendra B. Yadav , et Hajierah Davids , Charles B. de Koning , 6-Substituted imidazo[1,2-a]pyridines: Synthesis and biological activity against colon cancer cell lines HT-29 and Caco-2, *European Journal of Medicinal Chemistry*, vol. 46, p. 4573-4583, 2011.
- [85] Mahama O., Drissa S., Mamidou. W. K., et William Y., Composés á structure imidazopyridinyl-arylpropénone, nouveaux agents anti-infectieux potentiels, *Comptes Rendus Chimie*, vol. 19, n° 7, p. 850-856, juill. 2016, doi: 10.1016/j.crci.2015.10.014.
- [86] Hamdouchi C, Jesus de B., Mirian del P., Joseph G., Beverly A. H., et Lori V., 2-Amino-3-substituted-6-[(E)-1-phenyl-2-(N -methylcarbamoyl)vinyl]imidazo[1,2- a]pyridines as a

Novel Class of Inhibitors of Human Rhinovirus: Stereospecific Synthesis and Antiviral Activity, *Journal of Medicinal Chemistry*, vol. 42, n° 1, p. 50-59, janv. 1999, doi: 10.1021/jm9810405.

[87] Alain G., Sylvie M., Mohammed L., Ahmed E., Robert S., Graciela A., Olivier C., Jean-Claude T., Myriam W., Jan B., Erik De C., et Jean-Pierre C., Synthesis of Imidazo[1,2-a]pyridines as Antiviral Agents, *Journal of Medicinal Chemistry*, vol. 41, n° 25, p. 5108-5112, 1998, doi: 10.1021/jm981051y.

[88] Kristjan S. G., John C. D., Leroy B. T., The Condensation of 2,6-Dichloroimidazo[1,2-a]pyridine with Ribonolactone Gives a Novel Imidazo[1,2-a]pyridine C-nucleoside with an Unexpected Site of Ribosylation, *Tetrahedron Letters*, vol. 37, n° 14, p. 2365-2368, 1996.

[89] Kristjan S. G., John D. W., John C. D., et Leroy B. T., Synthesis and Antiviral Activity of Novel Erythrofuransyl Imidazo[1,2-a]pyridine C-Nucleosides Constructed via Palladium Coupling of Iodoimidazo[1,2-a]pyridines and Dihydrofuran, *Journal of Medicinal Chemistry*, vol. 46, p. 1449-1455, 2003.

[90] Jean-Paul D. U. G., Pierre-Olivier D., Mélanie P., Claude L. C., Cédric N., Mahama O., Cécile E. G., Alain G. et Hassan A., Discovery of imidazo[1,2-a]pyridine-based anthelmintic targeting cholinergic receptors of *Haemonchus contortus*, *Bioorganic & Medicinal Chemistry*, vol. 25, n° 24, p. 6695-6706, déc. 2017, doi: 10.1016/j.bmc.2017.11.012.

[91] Cyril F., Louise B., Clotilde B., Julien P., Sébastien H., Anita C., Caroline C. D., Nicolas P., Michèle L., Magali C., Sandra B. D., Mélanie P., Alix S. S., Valère B. M., Bertrand C., Elisa B. R., Marc S., Rachel M., Susan W. A. H. F., Alexis V., Pascal R., Pierre V., Patrice V., et Nadine A.; Nongenotoxic 3-Nitroimidazo[1,2- a]pyridines Are NTR1 Substrates That Display Potent *in Vitro* Antileishmanial Activity, *ACS Medicinal Chemistry Letters*, vol. 10, n° 1, p. 34-39, janv. 2019, doi: 10.1021/acsmchemlett.8b00347.

[92] Katerine. A. A., Jonathan A.G. C., Vickey L. S., Nicholas J. L., Mark J. P., Chrystala C., Raquel F., Carlos A., Modesto J. R., David B., Lluís B. et Gurdyal S. B., Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting *M. tuberculosis* QcrB, *PLoS One*, vol. 7, n° 12, p. e52951, déc. 2012, doi:10.1371/journal.pone.0052951.

- [93] Moraski G. C., Lowell D. M., Philip A. H., Helena B., Sanghyun C., Scott G. F., et Marvin J. M., Advent of Imidazo[1,2-*a*]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity, *ACS Medicinal Chemistry Letters*, vol. 2, n° 6, p. 466-470, juin 2011, doi: 10.1021/ml200036r.
- [94] López-Martínez M., Salgado-Zamora H., Campos-Aldrete M. E., Trujillo-Ferrara J. G., Correa-Basurto J., et Mexica-Ochoa C., Effect of the lipophilic parameter (log P) on the anti-parasitic activity of imidazo[1,2-*a*]pyridine derivatives, *Medecinal Chemistry Research*, vol. 21, n° 4, p. 415-420, avr. 2012, doi: 10.1007/s00044-010-9547-3.
- [95] Pratibha S., Deepa D., Mansi P., Latha N., Divyank M., Tapasya S. et Anudeep K. N., Exploration of Novel TOSMIC Tethered Imidazo[1,2-*a*]pyridine Compounds for the Development of Potential Antifungal Drug Candidate, *Research Square*, p.1-23, mars 2021. doi: 10.21203/rs.3.rs-352624/v1.
- [96] Renata B. L., Cleverton K. F. d. L., Leandro L. d. S., Nelilma C. R., et Ana L. P. M., Eliezer J. Barreiro, Carlos A. M. Fraga, Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-*a*]pyridine symbiotic prototypes, *Bioorganic & Medicinal Chemistry*, vol. 17, p. 74-84, 2009.
- [97] Tschitschibabin A.E., Zur Tautomerie des α -Amino-pyridins, IV. Mitteilung: Eine Darstellungsmethode des Pyrimidazols und seiner Homologen, *Berichte der Deutschen Chemischen Gesellschaft*, vol 58, n° 8, p. 1704-1706, 1925, <https://doi.org/10.1002/cber.19250580852>.
- [98] Mosby W. L., Heterocyclic Systems with Bridgehead Nitrogen Atoms, Part 1, *Interscience Publishers, Inc., New York*, vol 15, p. 461, 1961.
- [99] Andrés A. T., Gary T., Gregor J. M., Juan A. V., Ana I. d. L., Encarnación M., Aránzazu G., María L. L., Sergio A. A. d. D., José M. A., Daniel O., Abdelah A., et Wilhelmus D., Claire M., José I. A., Hilde L., et JoséMaría C., Imidazo[1,2-*a*]pyridines: Orally Active Positive Allosteric Modulators of the Metabotropic Glutamate 2 Receptor, *Journal of Medicinal Chemistry*, vol. 55, p. 2688-2701, 2012, doi: 10.1021/jm201561r. [100] Caroline C. D., Lucie P., Pierre V., Magali C., Christophe C., Sébastien H., Floriane T., Michèle L., Vincent

R., Anita C., Maxime D. C., Pascal R., Nadine A. et Patrice V., Targeting the human parasite *Leishmania donovani*: Discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series, *Bioorganic & Medicinal Chemistry*, vol. 21, n° 22, p. 7155-7164, nov. 2013, doi: 10.1016/j.bmc.2013.09.002.

[101] Brad D. M., Olivier G. B. et Kazunari O., The ¹⁴C, ¹³C and ¹⁵N syntheses of MON 37500, a sulfonylurea wheat herbicide, *journal of labelled compounds and radiopharmaceuticals*, vol. 48, p. 397-406, 2005, doi: 10.1002/jlcr.934.

[102] Alain G., Mohammed L., Ahmed E., Robert S., Graciela A., Olivier C., Jean-Claude T., Abdelali K., El Mokhtar E., Jean-Claude D., Myriam W., Yves B., Jan B., Erik D. C., et Jean-Pierre C., Synthesis of Acyclo-C-nucleosides in the Imidazo[1,2-a]pyridine and Pyrimidine Series as Antiviral Agents, *Journal of Medicinal Chemistry*, vol. 39, n° 14, p. 2856-2859, 1996.

[103] Jean-Michel C., Jan P., Vincent G., Damien C., Aure L. M. C. L., Alain G., Emmanuel M., Jean-Claude T., Olivier C., et Johan N., Synthesis and antiviral activity of an imidazo[1,2-a]pyrrolo[2,3-c]pyridine series against the bovine viral diarrhoea virus, *European Journal of Medicinal Chemistry*, vol. 45, p. 2044-2047, 2010.

[104] Shankarappa A. B., Venkatesh K. B., Yadav D. B., et Rajesh B., A novel method for the synthesis of 6-bromo-2-(3,4-dichlorophenyl) imidazo[1,2-a]pyridine using microwave irradiation, *Molbank*, p. 2, janv. 2009.

[105] Rajaa B., Angela R. A., Raphael B., Nicolas R., Mathilde C., Amelie B., Romain D., Said Y., Patricia Melnyk et Laurence Agouridas, Design and synthesis of 2,6-disubstituted-8-amino imidazo[1,2a]pyridines, a promising privileged structure, *Bioorganic & Medicinal Chemistry*, vol. 26, n° 12, p. 3296-3307, juill. 2018, doi: 10.1016/j.bmc.2018.04.057.

[106] Dongjian Z., Jiuxi C., Dengze W., Miaochang L., Jinchang D., et Huayue W., An efficient, catalyst- and solvent-free synthesis of imidazo[1,2-a]pyridines and 2,4-disubstituted thiazoles on grinding, *Journal of chemical research*, p. 84-86, 2009.

- [107] Dong-Jian Z., Jiu-Xi C., Miao-Chang L., Jin-Chang D., et Hua-Yue W., Catalyst- and Solvent-free Synthesis of Imidazo[1,2-a]pyridines, *Journal of the Brazilian Chemical Society*, vol. 20, n° 3, p. 482-487, 2009.
- [108] Katrin G., Lutz W. et Fridolin M., Synthesis of Imidazo[1,2-a] annulated Pyridines, Pyrazines and Pyrimidines by a Novel Three-Component Condensation, *Letters Synlett*, p. 661-663, 1998.
- [109] Martina H., Carmen B. R., Joanna M. W., Estel la B., Holger S., Manfred S. Z., Dieter S., Bettina H. et Ewgenij P., SAR-study on a new class of imidazo[1,2-a]pyridine-based inhibitors of 5-lipoxygenase, *Bioorganic & Medicinal Chemistry Letters*, vol. 22, n° 5, p. 1969-1975, mars 2012, doi: 10.1016/j.bmcl.2012.01.038.
- [110] Carlos Z. H., Unnamatla. M. V. B., et Gámez-Montaña R., Synthesis of Imidazo[1,2-a]pyridine-Chromones via Microwave-Assisted Groebke-Blackburn-Bienaymé Reaction, *Proceedings*, vol. 41, n° 1, p. 68, nov. 2019, doi: 10.3390/ecsoc-23-06652.
- [111] Taleb H. Al-T. et Raed A. Al-Q., Post Groebke–Blackburn multicomponent protocol: Synthesis of new polyfunctional imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine derivatives as potential antimicrobial agents, *European Journal of Medicinal Chemistry*, vol. 45, n° 12, p. 5848-5855, déc. 2010, doi: 10.1016/j.ejmech.2010.09.049.
- [112] Mehdi A., Mohammad M., Mahsa A. N. et Peiman M., Catalyst-free three-component reaction between 2-aminopyridines (or 2-aminothiazoles), aldehydes, and isocyanides in water, *Tetrahedron Letters*, vol. 48, p. 7263-7265, 2007.
- [113] Anneli N., Mikeal T. N., Olof L., Daniel M., Johan G., Samir Y., Luke R. O., Bachally R. S., Mats L., Sherry L. M. et Anders K., Synthesis, biological evaluation and X-ray crystallographic studies of imidazo[1,2-a]pyridine-based Mycobacterium tuberculosis glutamine synthetase inhibitors, *Medecinal Chemistry Communications*, vol. 3, n° 5, p. 620, 2012, doi: 10.1039/c2md00310d.

- [114] Ping L., Li-song F., Xinsheng L., et Guo-qiang L., Synthesis of imidazo[1,2a]pyridines via three-component reaction of 2-aminopyridines, aldehydes and alkynes, *Tetrahedron Letters*, vol. 51, p. 4605-4608, 2010, doi: :10.1016/j.tetlet.2010.05.139.
- [115] Prashant B. J., et Viskas N. T., ISetyternthesis of 3-Nitro-2-arylimidazo[1,2-a]pyridines Using Sodium Dichloroiodide, *Letter Synlett*, vol. 25, p. 2636-2638, 2014.
- [116] Litao A., Xiaojun S., Meng L., Jianfeng Z., Fengxia Z. et Hui Z., Metal-free oxidative coupling of aminopyridines with nitroolefins to imidazo[1,2-a]pyridine in the presence of I2–TBHP–pyridine, *De Gruyter*, p. 2-7, 2016, doi: DOI 10.1515/znb-2015-0171.
- [117] Juan A. V., Juan J. V, Julio A. B., Jesfis E. et Hamdouchi C., A New Approach to the Synthesis of 2- Aminoimidazo[1,2-a]pyridine Derivatives Through Microwave-Assisted N-Alkylation of 2-Halopyridines, *Tetrahedron Letters*, vol. 55, p. 2317-2326, 1999.
- [118] Zali-Boeini H., Norastehfara N., et Amiri Rudbaria H., One-step Synthesis of Imidazo[1,2-a]pyridines in Water, *Royal Society Of Chemistry*, p. 1-16, 2016, doi: 10.1039/C6RA17065J.
- [119] Eric P. A. T., Melodie R., Jeffrey M. M., et Dean F. T., Gold-Catalyzed Redox Synthesis of Imidazo[1,2-a]pyridines using Pyridine N-Oxide and Alkynes, *Advanced Synthesis and Catalysis*, vol. 356, p. 687-691, 2014, doi: DOI: 10.1002/adsc.201300996. [120] Mosby W. L., Heterocyclic Systems with Bridgehead Nitrogen Atoms, Part One, Interscience Publishers Inc.,.
- [120] D. P. Calfee, Methicillin-resistant Staphylococcus aureus and vancomycin resistant enterococci, and other Gram-positive in healthcare, *Curr. Opin. Infect. Dis.* 2012, 25, 385.
- [121] Payne, D.J. *Science*, 2008, 321, 1644-1645.
- [122] Theresa, L. S. *The New England Journal of Medicine*, 1999, 340, 493-501.